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IDENTIFYING THE MECHANISMS OF CHANGE AND IN-SESSION THERAPIST 
FIDELITY IN MEASUREMENT BASED CARE FOR DEPRESSION  
 
Despite its emergence as an evidence-based practice (Glasgow et al., 2014; Scott & Lewis, 
2014), there is a dearth of literature explicating how measurement-based care (MBC) achieves its 
positive effects in psychotherapy for depression. MBC involves the systematic use of client 
progress data to guide treatment decisions in therapy (Scott & Lewis, 2014). MBC has three key 
elements when applied with adherence: a) administration of a symptom measure; b) clinician and 
client review of symptom scores; and c) clinician and client discussion of symptom scores in 
session. Simply providing clinicians with feedback regarding client progress improves client 
outcomes (Lambert et al., 2003). Despite evidence supporting MBC’s effectiveness, a gap exists 
in the literature regarding the process and mechanisms by which MBC acts to produce change in 
depression symptoms.  
The present studies served to close this gap in the literature regarding how MBC is used in 
session and MBC’s potential mechanisms of action through the use of rigorous qualitative and 
quantitative modeling procedures. The present studies sought to achieve the following aims: Study 
1) To evaluate the variation in clinician approaches to integrating MBC into clinical sessions 
across treatment; Study 2) To identify patterns and trajectories of clinician MBC adherence 
following MBC training; and Study 3) To assess session attendance (i.e. treatment engagement) 
as a putative mechanism by which MBC may act to produce depression symptom change.  
Study findings suggested that clinicians generally responded to MBC feedback in line with 
Feedback Intervention Theory (Kluger & DeNisi, 1996), but also highlighted the complexities of 
clinician assessment and decision-making processes. Observable patterns of clinician MBC 
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adherence post training also emerged, and clinicians demonstrated significant variation in their 
MBC use. The studies, however, failed to identify treatment engagement as MBC’s mechanism of 
change.  Although additional research is needed to elucidate MBC’s causal processes, findings 
from the present studies may serve inform strategies to enhance implementation of MBC, improve 
outcomes for clients seeking psychotherapy, and reduce the burden of disease associated with 
depression.  
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General Introduction 
Depression remains one of the most impactful health conditions worldwide despite the 
existence of effective psychotherapy and pharmacological interventions. A 2016 report from the 
World Health Organization identified that nearly one in 10 individuals worldwide has a diagnosis 
of depression or anxiety, but that only 50% of individuals with symptoms actually receive 
treatment and only 40% receive effective treatment (World Health Organization, 2016). One 
barrier to accessing effective treatment is the substantial lag in the time between the development 
and empirical testing of interventions, revealing evidence based practices (EBPs), and the 
implementation of EBPs in community settings. In fact, in can take nearly two decades for even a 
small amount of research evidence about mental health interventions to move from the research 
“lab bench” to clinical application (Balas & Boren, 2000). Even when EBPs for depression are 
implemented in the community, they typically require substantial training and ongoing supervision 
and face numerous barriers to sustained use (e.g. clinician attitudes, low resources; Jensen-Doss 
& Hawley, 2010; Lewis & Simons, 2011; Stewart, Chambless, & Baron, 2012; Stirman et al., 
2012). Researchers have begun to explore minimal interventions needed to promote depression 
symptom change (i.e. MINCs; Glasgow et al., 2014) that are easily implemented in resource-
strained community mental health settings. Identification of these MINC’s may enable the 
implementation of only the core components of EBPs (i.e. the components that maximize symptom 
change) in order to maximize reach, reduce burden on clinicians, and enhance outcomes for 
community clients with depression.  
Definition and Evidence Supporting Measurement-Based Care 
Measurement-based care (MBC) is an EBP that is conceptualized as a MINC, with 
potential for far reaching impact on the global burden of depression. MBC can be defined as a 
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“feedback intervention” that involves the systematic use of client progress and outcome data, 
typically assessed by self-report prior to each clinical encounter, to guide treatment decisions in 
therapy sessions (Scott & Lewis, 2014). MBC has appeared in a number of formats in the literature 
from paper and pencil self-report measures to technologically advanced, electronic Measurement 
Feedback Systems that provide real-time graphs of client progress and clinical decision support 
(Lyon & Lewis, 2016). MBC is also known by many other names, including progress monitoring 
(Byrne, Hooke, Newnham, & Page, 2012; Goodman, McKay, & DePhilippis, 2013; Newnham, 
Hooke, & Page, 2010; Persons, Koerner, Eidelman, Thomas, & Liu, 2015), outcome monitoring 
(De Jong et al., 2014; Young, Grusky, Jordan, & Belin, 2014), and feedback systems (Connolly 
Gibbons et al., 2015; Kelley & Bickman, 2009). All of these names share a common thread of the 
use of psychometrically validated assessment tools to evaluate and enhance therapy progress and 
outcome.  
Simply having clinicians administer a self-report questionnaire and independently review 
client scores improves outcomes for clients  (Lambert et al., 2003). However, the impact of MBC 
is enhanced if the clinician reviews the symptom scores and provides feedback to the client about 
therapy progress via discussion in therapy (Lambert et al., 2005). Some of the earliest emerging 
evidence pointing to MBC’s effectiveness in psychotherapy came from Lambert and colleagues' 
(2005) work using the Outcome Questionnaire-45 (OQ-45) measurement feedback system. The 
OQ-45 measures symptom distress, interpersonal relationships, and social role functioning, and 
the feedback system enables the identification of clients as “on track” or “not on track” to improve 
in psychotherapy (Lambert & Finch, 1999). Lambert and colleagues’ meta-analysis of four studies 
exploring the effectiveness of the OQ-45 suggested that providing feedback to clinicians about 
client progress increased client session attendance, reduced deterioration, and enhanced 
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psychotherapy outcomes, especially for clients identified by the OQ-45 measure as not on track to 
improve (Lambert et al., 2003; Whipple et al., 2003).  
Since Lambert and colleagues (2003) seminal work, numerous studies have emerged 
providing evidence for MBC’s clinical effectiveness in reducing deterioration, improving 
outcomes, enhancing therapeutic relationships, and reducing treatment readmission for individuals 
seeking treatment for depression (Byrne et al., 2012; Crits-Christoph et al., 2012; Fortney et al., 
2016; Guo et al., 2015; Lambert et al., 2005; Newnham et al., 2010; Probst et al., 2013; W. Simon, 
Lambert, Harris, Busath, & Vazquez, 2012). For example, MBC implementation using the OQ-45 
in individual psychotherapy resulted in reduced clinical deterioration in a sample of inpatient 
clients with comorbid depressive disorders and somatoform disorders (Probst et al., 2013). 
Evidence also supports MBC’s effectiveness in enhancing psychotherapy outcomes for depression 
and anxiety disorders in both children and adults (Elmquist, Melton, Croarkin, & McClintock, 
2010; Newnham et al., 2010), and for identifying and monitoring clients at high risk of self harm 
and suicidal ideation (Restifo, Kashyap, Hooke, & Page, 2015). MBC may be beneficial in both 
short and long term therapies (De Jong et al., 2014) and youth and family therapy (Bickman, 
Kelley, Breda, de Andrade, & Riemer, 2011), though more research is needed to better understand 
the impact of MBC on long term treatment outcomes (De Jong et al., 2014).  
MBC has also been shown to enhance psychotherapy outcomes across a variety of client 
presenting problems beyond depression, including substance abuse (Crits-Christoph et al., 2012; 
Goodman et al., 2013) and eating disorders (Simon et al., 2013), among others. In addition, MBC 
has evidence supporting its use as a tool for both clinician professional development and for 
ongoing quality assurance at the organization level through the use of aggregate MBC symptom 
change data to evaluate treatment effectiveness (Fortney et al., 2016; Scott & Lewis, 2014). 
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Overall, there is robust and consistent evidence supporting MBC’s effectiveness as an EBP for a 
wide range of client presenting problems.  
MBC has also been studied extensively in pharmacotherapy as a method for providing 
physicians with feedback and clinical decision support regarding medication dosages and side 
effects for depression treatment. Trivedi and colleagues (2007) explored the clinical utility of MBC 
in their Sequenced Treatment Alternatives to Relieve Depression study (STAR*D), which aimed 
to evaluate the effectiveness of citalopram (a selective serotonin reuptake inhibitor) for remitting 
the symptoms of major depressive disorder. In the STAR*D trial, the Quick Inventory for 
Depressive Symptomatology (QIDS-C; Rush et al., 2003) and client ratings of side effect 
frequency, intensity, and burden served as the basis for MBC at each medication management 
visit. Physicians then automatically received feedback on symptom and side effect changes as well 
as optimal treatment adjustments (e.g. dosage of medication). MBC was ultimately effective for 
encouraging physicians to follow treatment recommendations at 85% of medication management 
visits with clients (Trivedi et al., 2007). Trivedi and colleagues suggested that the MBC approach 
may have had a positive impact on treatment effectiveness and depression remission rates through 
the mechanism of encouraging more accurate and timely dosage changes for clients (Trivedi et al., 
2006, 2007).  
More recent randomized controlled trials (RCT) provided additional support for Trivedi 
and colleagues’ (2007) work by comparing antidepressant medication management plus MBC to 
antidepressant treatment as usual. For example, Yeung and colleagues (2012) Clinical Outcomes 
in Measurement-Based Treatment (COMET) study found that clinicians who received monthly 
updates on client depression symptoms had clients who were more likely to respond to 
antidepressant medication and experience remission of symptoms in a primary care setting (Yeung 
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et al., 2012). In a separate RCT, Guo and colleagues (2015) also found that the clients receiving 
MBC alongside their medication management in outpatient treatment had better overall symptom 
improvement and improved more rapidly than those not receiving MBC. They also identified that 
clinicians who received MBC had higher rates of dosage adjustments in order to achieve the most 
effective medication dosage throughout treatment (Guo et al., 2015).  
In summary, MBC appears to be highly effective not only for tracking client progress in 
psychotherapy, but also for enhancing optimal medication dosage identification and more rapid 
dosage changes to maximize pharmacotherapy effectiveness. MBC’s effectiveness in 
pharmacotherapy provides insight into MBC’s potential mechanisms of action (i.e. more effective 
medication dosage), however additional research is needed in both psychotherapy and 
pharmacotherapy to identify how MBC works to produce change. 
Core Components of MBC and MBC Adherence 
There is substantial evidence supporting MBC as an effective intervention for promoting 
symptom change in both psychotherapy and pharmacotherapy. MBC’s treatment-enhancing 
effects appear to cut across diagnoses (e.g. depression, substance use), clinical settings (e.g. 
primary care, inpatient hospitals), and treatment formats (e.g. individual, couples). MBC appears 
to be most effective when feedback information is shared with both clinician and client, though 
treatment gains still occur when the clinician does not discuss symptom scores with the client (De 
Jong et al., 2014; Lambert et al., 2005). These findings raise important questions regarding the 
core components of MBC and the dosage of these components required to achieve depression 
symptom reduction. Based on the extant literature, our research team has articulated three key 
elements that are required for clinicians to demonstrate adherence to MBC: a) administering an 
empirically validated symptom measure (i.e. a self-report questionnaire) at the beginning of each 
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clinical session; b) clinician (and client)  review of symptom measure scores and score trajectories 
over time (if available); and c) clinician discussion of symptom scores with the client in session 
(Lewis et al., 2015).  
Research has yet to identify the dosage of these three components (i.e. administer, review, 
and discuss) required across psychotherapy treatment in order to observe enhanced outcomes. 
Many existing studies of feedback systems assume that clinicians use MBC at every session, and 
these studies either fail to discuss variability or note significant variation in clinician self reported 
MBC use. While it is clear that administration of a measure is a core component of MBC, much 
remains unknown about the frequency of administration truly needed to promote symptom change. 
Since many MBC effectiveness studies do not rely on clinicians to administer symptom measures 
at each session (e.g. by using research specialists or site administrative staff; Connolly Gibbons et 
al., 2015; Crits-Christoph et al., 2012; Lambert et al., 2005), it is not yet clear how frequently 
clinicians would choose to administer MBC measures and the impact that variable administration 
might have on outcomes. Given that Dowrick and colleagues (2009) suggest that the 
administration process may be key to client self-reflection on symptoms, more research is needed 
to determine at what minimal frequency measures must be administered to drive MBC’s effects. 
A second consideration regarding the core components of MBC is the degree to which 
score review may be core to MBC’s effects. In a study of MBC in an urban community mental 
health setting, 89% of clinicians reported always reviewing score information (Connolly Gibbons 
et al., 2015). In contrast, a study by Bickman and colleagues (2016) reported that clinicians 
accessed symptom scores for 45% to 71% of various administered measures for youth receiving 
outpatient psychotherapy. However, simply accessing MBC score information does not 
necessarily imply that the clinician actually reviewed the scores.  Bickman and colleagues (2016) 
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also report enhanced treatment outcomes with increased clinician MBC administration and review, 
though these results were specific to one specific clinic. In summary, the literature reflects 
significant variability in the degree to which clinicians choose to review symptom scores for each 
clinical session. Despite variability in review frequency, these studies still showed enhanced 
treatment outcomes with MBC administration for clients receiving psychotherapy for depression 
and other clinical diagnoses (Bickman et al., 2016; Connolly Gibbons et al., 2015). Additional 
research is needed to evaluate the degree to which review of symptom scores is core and the 
frequency of score review that is necessary to achieve enhanced depression symptom change.  
Finally, results in the MBC effectiveness literature suggest that discussion of client 
progress between clinician and client in session enhances outcomes above and beyond simple score 
review (Lambert et al., 2003). However, over half of clinicians (57%) in Lambert and colleagues 
(2001) research reported only sometimes, rarely, or never choosing to discuss symptom score 
information with their clients. Gibbons and colleagues (2015) reported that 67% of clinicians 
reported discussing symptom scores with clients (Connolly Gibbons et al., 2015). The clinicians 
that chose to discuss MBC reported using it to inform treatment plans, change therapy approaches, 
change the problem focus, or review clinical books and materials (Connolly Gibbons et al., 2015). 
The limited literature on discussion appears to indicate substantial variability in both clinicians 
decisions to discuss MBC scores and the impact of these discussions on treatment. However, many 
studies fail to assess how frequently clinicians discuss MBC in session, and those that do often 
rely on retrospective clinician self-report of discussion at a single time point. Even fewer studies 
report details about the content of discussion in session and how MBC impacted treatment, two 
elements of MBC application that may drive symptom change. As with the other two components 
of MBC that may be “core” (i.e., administration and review of scores), more exploration is needed 
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to evaluate how often discussion should occur, and what type of discussion (e.g. clinician and 
client reflecting on change, discussing treatment plan changes, setting new treatment goals) is 
needed to promote symptom change. 
Despite significant support for MBC’s effectiveness as an intervention, many questions 
remain unanswered regarding how MBC works to optimize outcomes for depressed clients. First, 
it is necessary to better understand the dosage of MBC elements (administration, review, 
discussion) that is critical to MBC’s effectiveness. This may be explored by evaluating the relation 
between clinician use of these three MBC components and clinical outcomes to determine whether 
and how much of each are needed to enhance symptom change. Second, more research is needed 
to identify whether and how clinicians use MBC to change treatment when they do opt to review 
and discuss scores with the client in the therapy room. These insights regarding clinician session-
by-session MBC use may shed light on its core components and mechanisms of action, thereby 
facilitating recommendations for the broad implementation of MBC. 
The Present Studies 
The present studies expanded upon previous literature by characterizing the variation in 
clinician approaches to integrating MBC into clinical sessions across treatment through qualitative 
and quantitative methods. The present studies sought to achieve the following aims: Study 1) To 
evaluate the variation in clinician approaches to integrating MBC into clinical sessions across 
treatment; Study 2) To identify patterns and trajectories of clinician MBC adherence following 
MBC training; and Study 3) To assess session attendance (i.e. treatment engagement) as a putative 
mechanism by which MBC may act to produce depression symptom change.  
The present studies served to close a gap in the literature regarding how MBC is used in 
session, dosage of MBC required, and the potential mechanisms of action of MBC for enhancing 
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clinical outcomes through the use of rigorous qualitative and quantitative modeling procedures. 
These studies will be some of the first to elucidate how MBC functions in session to engender 
improvements in adult client depression symptoms. Findings from the present studies may serve 
to identify the core elements of MBC that must occur and how often, which may ultimately inform 
efforts to widely implement MBC, enhance outcomes for community clients, and reduce the 
burden of disease associated with depression.  
General Methods 
Parent Study Aims and Design 
The present studies were explored by leveraging data from 10 of 12 sites engaged in a four-
year NIMH-funded R01 pragmatic randomized implementation trial (RCT; Lewis et al., 2015). 
The parent R01 sought to compare standardized and tailored approaches to MBC implementation 
using the Patient Health Questionnaire-9 item depression symptom self-report questionnaire 
(PHQ-9; Kroenke, Spitzer, & Williams, 2001) within Centerstone, the nation’s largest provider of 
behavioral health services. The aims of the parent R01 study include: a) comparing the effect of 
standardized versus tailored MBC implementation on clinician-level implementation and client-
level symptom outcomes; b) identifying contextual mediators of MBC adherence; and c) exploring 
the differential impact of MBC adherence in the two implementation conditions on client 
outcomes.  
Implementation Conditions 
To achieve these aims, 12 Centerstone sites across two states (Indiana and Tennessee) were 
randomized to either standardized or tailored implementation approaches. The standardized 
implementation sites completed a baseline assessment, four-hour MBC workshop, and hour-long 
triweekly consultation meetings that focused on maximizing clinician MBC adherence (i.e. PHQ-
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9 administration at each session, review of PHQ-9 scores, and discussion of the PHQ-9 in session). 
Conversely, sites randomized to the tailored implementation condition completed the baseline 
assessment and customized four-hour MBC workshop followed by triweekly implementation team 
meetings. These implementation team meetings established a guideline for frequency of MBC use 
at each site, whereas standardized sites were instructed to use MBC each session. Additionally, 
implementation teams focused on identifying site-specific contextual barriers to MBC 
implementation and generating targeted implementation strategies (e.g. distributing educational 
materials, making changes to MBC procedures; Powell et al., 2015) to reduce the impact of these 
barriers and maximize MBC use (see Lewis et al., 2015). To increase the feasibility of the R01 
study, workshop trainings were conducted in four cohorts (number of sites in each cohort: 2, 4, 4, 
2) spaced five months apart to support active implementation. The 12 clinics were matched on size 
and rural/urban status and then randomly assigned first to training cohort and second to 
implementation condition. 
Data Collection and Assessment Procedures 
Data collection. After receiving MBC workshop training, each of the sites began a five-
month active implementation period followed by 10 months of sustainment. Standardized 
consultation and tailored implementation team meetings were held during the five-month active 
implementation period. Clinicians then completed a follow up assessment at five months following 
training, and then began the sustainment period of 10 months to evaluate continued use of MBC. 
Exit interviews were conducted with a sampling of clinicians at 10 months following training (i.e. 
five months after the end of active implementation), and clinicians completed an additional follow-
up assessment at 15 months post training (i.e. after active implementation and sustainment is 
complete). Data were also collected on clinician session-by-session PHQ-9 completion and MBC 
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adherence. Additionally, approximately three clients per clinician were enrolled in the study and 
were assessed by research staff at baseline and treatment week 12 using the PHQ-9.  
EHR modifications. The use of MBC was facilitated for clinicians through several 
alterations to the Electronic Health Record (EHR) systems across all 12 sites. First, clients who 
presented to the site with symptom of depression were flagged in the EHR as being on the 
depression pathway. Intake staff, study research staff, or clinicians could enroll clients in the 
pathway. This depression pathway indicator served as a clinical decision support tool that allowed 
clinicians to identify the clients with depression for whom MBC with the PHQ-9 would be most 
appropriate. Throughout the active implementation and sustainment period, clinicians were asked 
to report on their use of the PHQ-9 by entering the scores into the modified EHR. The EHR 
automatically graphed the clients score trajectories over time, enabling clinicians to observe 
changes in PHQ-9 scores over the course of treatment. In addition to PHQ-9 score entry, clinicians 
in Tennessee also indicated whether they viewed the PHQ-9 score trajectory graph or discussed 
the PHQ-9 in session by checking boxes on their electronic progress notes.  Clinicians in Indiana 
automatically received credit for viewing the score trajectory each time they accessed the graph 
due to differences in EHR software. Like Tennessee, Indiana clinicians also had to check a box in 
the EHR to indicate that they discussed the PHQ-9 in session. In the event that the PHQ-9 was not 
completed during a session, clinicians in both states were asked to check a box on their progress 
note indicating why the PHQ-9 was not completed (e.g. time limitations, technology problems, 
PHQ-9 not relevant or helpful). In both states, these MBC related questions in the EHR were 
optional.  
The main clinician-level outcome pulled from the parent R01 for the present studies was 
clinician-reported MBC adherence data collected in the EHR: a) PHQ-9 completion (yes/no); b) 
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review of score graph (objectively collected in IN and subjectively reported yes/no in TN); and c) 
discussion of scores in session (yes/no). The main client-level outcome was change in depression 
symptoms per the PHQ-9 measure at baseline (beginning of treatment), treatment week 12 as 
reported in a phone interview, and at the end of active implementation (treatment month 5 data 
pulled from the EHR).  
It is important to note that data for the present studies did not include implementation 
condition (i.e. standardized or tailored) as a variable of interest because the studies sought to 
answer specific questions about the variation in MBC implementation within the clinician-client 
dyad. Since MBC was used in clinical sessions at each site regardless of the implementation 
approach, all data was integrated across conditions to maximize data variation and power.  
Participants 
Clinicians. Clinicians providing individual psychotherapy to adult clients for whom 
depression was a treatment focus at the 12 randomized Centerstone sites were recruited for 
participation in the parent R01 study and explored in the present studies. Quantitative data for the 
present studies included clinicians from cohorts one, two, and three (10 sites) from the parent R01, 
while qualitative data included clinicians from the six sites in cohorts one and two given the 
dynamic nature of the parent R01 design and the timing at which clinicians completed the exit 
interviews (i.e., in the sustainment phase 10 months after MBC training).  
Clients. Adult clients just beginning or continuing ongoing individual psychotherapy for 
depression with an enrolled clinician were eligible for participation in the parent R01 study. All 
clients included in the present studies were enrolled on the Centerstone depression pathway, an 
initiative that provides clinicians with a clinical decision support tool to identify clients for whom 
MBC with the PHQ-9 would be appropriate. To be part of the depression pathway, clients needed 
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to have a depression diagnosis (i.e. major depressive disorder, dysthymic disorder, depressive 
disorder NOS, adjustment disorder with depressed mood; see Appendix B). A subset of depression 
pathway clients was formally enrolled in the parent R01 study (approximately three clients per 
enrolled clinician). To be formally enrolled, clients had to be age 18 and above, have received a 
depression diagnosis, have a PHQ-9 total score > 9 on a research specialist administered phone 
screen, have received individual psychotherapy during the study enrollment period, and had to be 
fluent in English. Clients were excluded if they could not provide verbal consent (e.g. due to 
inability to read, severe mental illness). Clients formally enrolled in the study consented to provide 
demographic information and baseline and week 12 PHQ-9 symptom data (see Appendix A for 
list of all study measures).   
General Measures  
Clinician and client demographics. Demographic information was collected from both 
clinicians and clients at baseline assessment, with additional demographic variables pulled from 
Centerstone Human Resources or the EHR. Clinician demographic variables included: gender, 
age, race, ethnicity, highest degree attained, licensure status, current status as a clinical supervisor, 
frequency of clinical supervision, primary theoretical orientation, years of experience as a 
therapist, and number of clients seen. Client demographic variables included: gender, age, race, 
ethnicity, sexual orientation, relationship status, employment status, occupation, years of school 
completed, educational level, number of children, number of children living at the primary 
residence, number of individuals living in the primary residence, and native language. Several of 
these demographic measures were included as predictor or control variables in the present studies.   
Client symptom data (PHQ-9). The PHQ-9 is the most widely used, psychometrically 
validated measure of depression symptoms (Kroenke et al., 2001). The PHQ-9 is a 10-item 
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depression symptom self-report questionnaire that is sensitive to weekly changes in depression 
symptoms (Löwe, Kroenke, Herzog, & Gräfe, 2004), with increases in total scores indicative of 
higher severity symptoms. Clients respond to nine questions about their depression symptoms that 
map onto the core symptoms of depression in the Diagnostics and Statistics Manual (DSM; APA, 
2013) over the past two weeks using a Likert scale of “0 not at all” to “3 nearly every day.  The 
measure also includes a tenth item that inquires about the degree to which symptoms have led to 
impairment in role functioning. PHQ-9 scores are computed by summing the scores from each of 
the nine symptom items. Total scores may be indicative of minimal depression (score range from 
zero to four), mild depression (scores five to nine), moderate depression (scores 10 to 14), 
moderately severe depression (scores 15 to 19), or severe depression (scores 20 to 27).  A five-
point change in PHQ-9 total score is indicative of clinically significant change in symptoms 
(Kroenke & Spitzer, 2002), and clinicians received training to use this five point change in 
symptoms (or lack thereof) to guide treatment. The PHQ-9 was employed in two ways for the 
present studies: a) for clinicians to use in each session for MBC to obtain weekly symptom severity 
scores; and b) to measure change in client depression symptom severity at baseline, week 12 (via 
telephone assessments with research specialists) and at the end of the active implementation period 
(via EHR). 
Clinician reported MBC adherence. MBC adherence was measured using clinician-
reported adherence data collected in Centerstone’s EHR system within the client progress note for 
each therapy session. A “0” response for adherence indicates that the PHQ-9 was not completed. 
PHQ-9 adherence was coded as a “1” if client PHQ-9 score data were entered into the EHR. If 
client PHQ-9 score data were entered and the clinician only reviewed or discussed the PHQ-9 
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scores, PHQ-9 adherence was coded as a “2.” Adherence was coded as a “3” if scores were entered, 
reviewed, and the clinician reported discussing the PHQ-9.  
Data Screening and Missing Data 
All quantitative analyses employed a maximum likelihood procedure where possible to 
include all available data and avoid listwise deletion of cases. Multiple imputation was employed 
to account for missing data in covariates to be included as independent variables in quantitative 
study regression models. Twenty data sets were generated using Markov chain Monte Carlo in 
Mplus statistical software to identify plausible values for imputation (Tihomir Asparouhov & 
Muthén, 2010; Schunk, 2008). All quantitative analyses were completed with the average of all 20 
imputed data sets. 
Chapter 1: Study 1 Introduction 
Although it appears that providing feedback to both therapists and clients about client 
progress is optimal for enhancing treatment (Lambert et al., 2005), research has yet to identify how 
this feedback process informs clinician behavior in the clinical session to create depression 
symptom change. For example, clinicians may use MBC feedback as it is used in pharmacotherapy 
to inform treatment plan changes and selection of more effective treatment interventions. 
Alternatively, clinician discussion of symptom scores in session may enhance client engagement 
by actively attending to client treatment progress while simultaneously improving reciprocal 
understanding of symptoms. However, it is not well understood how receiving MBC feedback 
about client progress impacts clinicians’ behavior in session. 
Feedback Intervention Theory 
One theory that may inform clinician in-session response to feedback is Feedback 
Intervention Theory (FIT; Kluger & DeNisi, 1996). The FIT is an integration of established basic 
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self-regulation theories including goal setting theory (Locke & Latham, 2002) and control theory 
(Carver & Scheier, 1982), which both suggest that individuals are motivated to resolve 
discrepancies between personal goals and current behavioral performance. FIT posits that in order 
to maximize reward, individuals are likely to shift their attention to their behavior when they 
receive feedback that there is either a gap between their current performance and an established 
standard of performance (negative feedback), or that they are performing well (positive feedback). 
This attention on the “self” is then theorized to produce affective change and arousal (e.g. anxiety 
for negative feedback or excitement for positive feedback), ultimately resulting in motivation to 
reduce the gap between personal performance and the standard (negative feedback) or to set a 
higher performance standard (positive feedback).  
In addition to feedback responses noted above, FIT theory highlights more nuanced 
responses to feedback that depend upon the characteristics of the behaviors required to enhance 
performance (Kluger & DeNisi, 1996). For example, an individual may be more likely to improve 
their performance on a task if behavior change is in line with their personal goals, if the individual 
feels efficacious in implementing the behaviors, and/or if the behaviors are likely to actually result 
in improved performance (DeNisi & Kluger, 2000). If these three conditions are not met, feedback 
may not result in increased motivation or behavior change. Instead, FIT suggests that when a 
feedback intervention highlights that an individual is either performing poorly (negative feedback) 
or well (positive feedback), he or she may engage in any of the following four behaviors: a) the 
individual can change his or her behavior to improve performance; b) he or she can abandon the 
standard of performance if behavior changes are unlikely to improve performance; c) he or she can 
modify the standard to reduce or increase expectations for performance; or d) he or she may reject 
the feedback provided and make no behavioral changes (Kluger & DeNisi, 1996).  
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MBC as a Feedback Intervention 
FIT has commonly been evaluated in management and business settings as a theory to 
guide feedback interventions provided to employees regarding their task performance at work.  For 
example, FIT has been used to evaluate employee behavioral responses to feedback regarding 
absenteeism at work (Gaudine & Saks, 2001), and general work performance (Kluger & DeNisi, 
1996). To our knowledge, the FIT model has yet to be explored in the context of a mental health 
intervention like MBC. MBC may be conceptualized as a feedback intervention as it can highlight 
gaps between actual and expected client depression symptom change in psychotherapy. In the case 
of MBC, the clinician’s performance is reflected in the client’s actual symptom improvement in 
therapy, while the standard refers to the expected symptom change after a certain amount of time 
in treatment. For example, clinicians participating in the parent R01 received training that a five-
point change in symptoms on the PHQ-9, either up or down, is considered clinically significant 
and may warrant changes to treatment (Lewis et al., 2015). Alternatively, studies by Lambert and 
colleagues have compared individual client progress to national norms of change on the OQ-45, 
thereby providing a standard of change to which clients are compared (Lambert et al., 2003).   
Once a client standard of change is established, MBC provides feedback to clinicians to 
highlight when clients are not making progress or are deteriorating in treatment (i.e. negative 
feedback) or when client symptom change meets or exceeds expectation (positive feedback). MBC 
feedback appears to be especially helpful in cases where the feedback is negative, as it enhances 
outcomes most effectively for clients not making progress (Lambert et al., 2001, 2005). Regardless 
of whether feedback is positive or negative, FIT predicts that clinicians may be prone to select one 
of the following behavioral approaches: a) make a change to the treatment or session plan (change 
behavior); b) expect that the client is unlikely to improve or has improved enough and do nothing 
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(reject the standard); c) expect a unique rate of improvement for a client and adjust goals (change 
the standard); or d) decide that the MBC feedback is inaccurate and do nothing (reject the feedback; 
Kluger & DeNisi, 1996).  
While FIT may provide useful insight into how clinicians use MBC, extant work using FIT 
emphasizes the impact of feedback only on individuals’ behavior. In contrast, a therapy session 
involves the clinician-client dyad, therefore client responses to both feedback and the clinician’s 
behavior may also play a role in the effectiveness of MBC. For example, a clinician who discusses 
MBC scores in session and uses them to make changes to the treatment plan may have clients who 
are more engaged in treatment and who attend more sessions (Eisen, Dickey, & Sederer, 2000). In 
contrast, a clinician may struggle to make changes to the focus of a session if the client is unwilling 
to make behavioral changes or believes that the feedback is inaccurate. Further exploration of the 
FIT’s potential for explaining how MBC is used in mental healthcare and how MBC impacts both 
clinician and client behavior has been recommended in the literature (Carlier et al., 2012; Lyon & 
Lewis, 2016). However, additional research is needed to formally test the utility of the FIT model 
for explaining the variation in clinician behavior resulting from using MBC, as well as the impact 
of this behavior change on client symptom outcomes.  
The Present Study  
The present study will leverage data from the parent R01 trial (see details above) to close 
a gap in the literature regarding how MBC is used in session and the degree to which the FIT 
model can accurately capture clinicians’ in-session MBC behaviors. The present study will employ 
qualitative analytic methods to evaluate variation in clinician approaches to integrating MBC into 
clinical sessions across treatment (Study 1 aim). It may also promote better understanding of how 
clinicians approach clinical decisions based on the nature of feedback (positive or negative), and 
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identify the degree to which an individual behavior change theory like FIT can capture these 
decision making processes. Additionally, results of this study may have implications for 
understanding the degree to which different clinician behavioral responses to feedback result in 
enhanced outcomes for clients, thereby highlighting additional putative mechanisms of action to 
be tested in future research efforts.  
Hypotheses  
It was anticipated that clinicians would employ MBC in line with FIT model and would 
change their behavior, reject the feedback, reject the standard of symptom change, or change the 
standard of symptom change upon receiving feedback about client progress from MBC (Kluger & 
DeNisi, 1996). These responses to feedback were expected to vary based on the sign of the 
feedback (i.e. positive or negative), such that clinicians who receive feedback showing the client 
is making progress (positive feedback) may choose to not change their behavior, but also may not 
reject the feedback (i.e. because they agree with the feedback that the client is making progress). 
In these cases, it is hypothesized that some clinicians may diverge from the FIT model responses 
such that they accept the feedback as accurate but choose not to make changes to their behavior or 
the standard of symptom change as they believe the client has made adequate progress and no 
changes are required. 
Study 1 Methods 
Participants 
 Clinicians were selected for exit interview participation from six of the 12 participating 
clinic sites. These sites were selected due to the timing of the parent R01 cohort design, as only 
six clinic sites had reached the 10 month post MBC workshop training timeline required for exit 
interview participation. Clinicians were eligible for participation in the exit interview if they had 
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completed MBC workshop training and follow-up surveys at five months post training (total 
clinician N = 51). The recruitment goal was to select approximately six clinicians per site for exit 
interviews using purposeful sampling, or the systematic selection of participants based on research 
questions (Palinkas et al., 2013). In the present study, purposeful sampling was to be achieved by 
identifying and completing exit interviews with equal numbers of clinicians with “low,” 
“medium,” and “high” MBC use in order to capture the full range of ways in which MBC was 
implemented among clinicians (Palinkas et al., 2013). However, difficulties in successful 
recruitment of clinicians and lack of availability of MBC use data from the EHR in the recruitment 
timeline resulted in the need to reach out to all eligible clinicians for participation and 
categorization of “low,” “medium,” and “high” use clinicians after completion of the exit 
interviews. The final sample of completed exit interviews included two to four clinicians from 
each site and a final N of 16 clinicians. The sample of enrolled clinicians included therapists, 
psychiatrists, interns, and clinical supervisors. See Table 1 below for number of eligible and 
recruited clinicians across sites. 
Table 1. Distribution of exit interview eligible and participating clinicians across sites. 
Site Eligible Clinicians Participating Clinicians 
1 9 1 
2 15 5 
3 6 1 
4 9 3 
5 7 4 
6 5 2 
  
Measures 
Exit interviews. Qualitative data was collected through a series of one-on-one, semi-
structured exit interviews, which took place approximately 10 months (range of 9-13 months) 
following completion of MBC workshop training. All interviews were conducted by phone by a 
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trained research specialist and lasted between 30 minutes and an hour. The study PI (Scott) trained 
two post-baccalaureate research specialists to conduct the exit interviews. Training involved an 
initial meeting to review exit interview questions, followed by the research specialists completing 
mock interviews with at least two study staff unfamiliar with the exit interview content. The study 
PI then reviewed each of the mock interviews and met with the research specialists to provide 
group feedback regarding interviewing skills. The research specialists were also trained in 
confidentiality procedures and in techniques for handling clinician distress prior to completion of 
the interviews. Specifically, they were trained to validate clinicians’ concerns, to reaffirm that 
participation in the interview is voluntary, and to discontinue interviews in the event that clinicians 
withdraw consent or become distressed, though the likelihood of the latter is low given the nature 
of the interview content. The study PI reviewed two additional interview recordings approximately 
two months into the interviewing process to provide ongoing feedback on interview 
implementation. The interviews were recorded using BlueJeans conference call recording software 
and subsequently submitted to a professional company for transcription.  
The FIT-guided questions in the interview consisted of four multiple-choice scenarios that 
asked clinicians to select both a quantifiable response (i.e. A, B, C, or D) and provide an example 
of why they selected their response.  The questions inquired about the subject’s typical response 
to situations in which they received PHQ-9 scores showing that their client was deteriorating 
(feedback sign: negative), making progress (feedback sign: positive), or not making progress 
(feedback sign: negative). The response choices that were provided were based on the behavioral 
responses predicted by FIT, which suggests that the clinicians can respond to feedback in one of 
four ways: a) change their behavior to improve outcomes by making a change in the treatment 
plan; b) reject the standard of change expected for their client and do nothing (e.g. they believe 
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that the client is unlikely to improve/they believe the client has improved enough); c) change the 
standard (e.g. they expect the rate of client improvement to be unique); or d) reject the feedback 
and do nothing (e.g. they believe that the PHQ-9 feedback is inaccurate) (Kluger & DeNisi, 1996). 
An “other” option was also offered to clinicians in order to provide them the opportunity to report 
a behavioral response that fell outside of those predicted by FIT. After selecting a response, 
subjects were probed by the research specialist to provide details about the reasoning behind their 
choices (see Table 2 for FIT questions).  
MBC Use Level. Following completion of clinician exit interviews, MBC penetration data 
(i.e. percentage of sessions where PHQ-9 was administered to clients out of those sessions where 
PHQ-9 could have been administered) and adherence data (i.e. whether clinicians administered, 
reviewed, and/or discussed the PHQ-9 at each therapy session with clients) were examined to 
identify clinicians as “low,” “medium,” and “high” MBC users (see Participants section above for 
more details). Mean penetration and adherence scores were obtained for each clinician based on 
their monthly PHQ-9 penetration and adherence data for all depression pathway clients collected 
over the five-month active implementation period (five months after receiving training in MBC). 
To compute average penetration, the number of PHQ-9s completed by each clinician was 
compared to each clinician’s possible PHQ-9s that could have been completed for eligible clients 
over the five-month period. This calculation was multiplied by 100 to obtain a percent and was 
reported as an average percent penetration value for each clinician.  
To compute average adherence, a MBC adherence score of “0” (no PHQ-9 completed), “1” 
(PHQ-9 completed only), “2” (PHQ-9 completed and score either reviewed by clinician or 
discussed in session), or “3” (PHQ-9 completed, reviewed by clinician, and score discussed in 
session) was assigned to each therapy session for which adherence data was available for all 
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depression pathway clients. Average adherence scores were then computed by averaging all 
session adherence scores and then dividing by the total number of therapy sessions completed. 
This calculation resulted in each clinician receiving an average adherence score ranging from “0,” 
or low adherence, to “3,” high adherence. 
A tercile split was then performed on both the penetration and fidelity data to categorize 
each of the participating clinicians as “low,” “medium,” or “high” MBC users based on the 
convergence of the penetration and adherence data (i.e. clinicians who score low, medium, and/or 
high on both penetration and adherence will be categorized as “low” “medium” or “high,” 
respectively). In the event that the penetration and adherence data did not converge, clinicians were 
assigned to the group that would minimize overestimation of use (i.e. “high” on penetration and 
“medium” on adherence would result in assignment to the “medium” group). This measure of 
MBC use enabled the contextualization of differences in the qualitative exit interview data that 
resulted from clinician variability in MBC application (i.e. high use clinicians having unique 
responses to questions compared to low use clinicians). 
Qualitative Coding Procedures 
Initial coding procedure and establishing inter-rater reliability. Transcripts from the 
exit interviews were coded using qualitative content methods and reflexive team analysis 
(Graneheim & Lundman, 2004; Hsieh & Shannon, 2005) to identify the common themes in 
clinician responses to MBC feedback and to evaluate therapist responses that diverged from the 
FIT model. Given the study’s aim to evaluate the FIT model, qualitative coding focused on four 
questions within the exit interviews (See Table 2) that included multiple choice responses inquiring 
about clinicians’ feelings about using the PHQ-9 and their responses to PHQ-9 scores showing 
progress, no progress, or clinical deterioration.  
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In the first step of the coding process, a coding team consisting of the study PI, a Ph.D. 
level qualitative coding expert, and two research specialists independently reviewed two full exit 
interview transcripts to identify potential codes for inclusion in a coding dictionary. The coding 
team met weekly for approximately one month to come to consensus regarding common themes 
from the two transcripts, develop main code names, assign definitions to each main code, and 
compile the final coding dictionary. Given the focus on the four exit interview questions 
highlighted above, the main codes established reflected the responses to the four questions (see 
Table 2 for list of codes) The coding team then independently applied the established coding 
dictionary to two additional exit interview transcripts and met to discuss the coding process in 
order to ensure saturation of themes (i.e. that all FIT transcript content was able to be coded with 
established codes).  
Table 2. FIT related exit interview questions and responses/main codes. 
Question Response Options/Main Codes 
How do you feel overall about using the PHQ-
9 in session? 
 
 
  
 
 
A. Made a change to the treatment or session 
plan – How?(change behavior) 
B. Set new treatment goals better matched to 
your client – How?(adjust standard of 
change) 
C. Did nothing to change treatment because 
client is improving – Why? (abandon 
standard of change) 
D. Did nothing to change treatment because 
you felt the PHQ-9 was inaccurate – 
Why?(reject feedback) 
E. Other 
 
When you received PHQ-9 scores showing 
your client was not making progress (feedback 
sign: negative), you typically: 
 
A. Made a change to the treatment or session 
plan – How?(change behavior) 
B. Set new treatment goals better matched to 
your client – How?(adjust standard of 
change) 
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C. Did nothing to change treatment because 
client is improving – Why? (abandon 
standard of change) 
D. Did nothing to change treatment because 
you felt the PHQ-9 was inaccurate – 
Why?(reject feedback) 
E. Other 
 
When you received PHQ-9 scores showing 
your client was deteriorating (feedback sign: 
negative), you typically: 
 
A. Made a change to the treatment or session 
plan – How?(change behavior) 
B. Set new treatment goals better matched to 
your client – How?(adjust standard of 
change) 
C. Did nothing to change treatment because 
client is improving – Why? (abandon 
standard of change) 
D. Did nothing to change treatment because 
you felt the PHQ-9 was inaccurate – 
Why?(reject feedback) 
E. Other 
 
When you received PHQ-9 scores showing 
your client was making progress in treatment 
(feedback sign: positive), you typically: 
 
A. Made a change to the treatment or session 
plan – How?(change behavior) 
B. Set new treatment goals better matched to 
your client – How?(adjust standard of 
change) 
C. Did nothing to change treatment because 
client is improving – Why? (abandon 
standard of change) 
D. Did nothing to change treatment because 
you felt the PHQ-9 was inaccurate – 
Why?(reject feedback) 
E. Other 
 
Once the coding dictionary was established for the exit interviews, the study PI and two 
research specialists formally coded the 16 exit interviews using Atlas.ti software (Muhr, 1997). 
All three coders coded four transcripts, meeting weekly to establish inter-rater reliability through 
a reflexive team approach (i.e. reflecting on each code assigned and coming to consensus regarding 
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coding disagreements). Once over 10% of the transcripts were coded by the full team including 
study PI with minimal reliability issues, the research specialist coders were cleared to 
independently code the remaining 12 transcripts. Inter-rater reliability meetings were held weekly 
with the study PI and research specialists, with the study PI providing oversight and knowledge of 
the coding dictionary to resolve coding disagreements within each of the transcripts coded.  
Sub-coding procedure. Once all transcripts had been coded and inter-rater reliability was 
established for each of the 16 transcripts, the study PI and lead research specialist independently 
reviewed all clinician quotes coded with the FIT-relevant “Feelings about Using PHQ-9 in 
Session,” “Response to PHQ-9 Scores Showing No Progress,” “Response to PHQ-9 Scores 
Showing Deterioration,” and “Response to PHQ-9 Scores Showing Progress” codes (see Table 2). 
This independent review process served two purposes: a) to identify common patterns of clinician 
behavioral approaches using FIT (i.e. changing behavior, changing goals, rejecting feedback due 
to inaccuracy, rejecting feedback due to client being unlikely to change, or other); and b) to identify 
potential sub-codes that would enable elaboration on how clinicians adjusted behavior in session 
as a result of receiving PHQ-9 feedback. 
The study PI and lead research specialist met to discuss common themes and come to 
consensus on potential sub-codes to capture additional variation in clinician responses (i.e. codes 
within each of the FIT-relevant main codes above). For example, a sub-code of “adding additional 
treatment services” was added to identify a specific way that a clinician made changes to treatment 
in response to scores showing deterioration. Twenty-three sub-codes were identified through this 
reflexive consensus process (see Table 3 below for list of sub-codes). 
Table 3. List of identified sub-codes for FIT behavioral responses to PHQ-9 feedback. 
Clinician FIT Response Sub-code 
Change the therapy treatment plan  
(change behavior) 
Clinician/client identification of session focus 
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 Client request for treatment plan changes 
 Trying new treatment approaches 
 Identification of client core problem/symptom 
 Change treatment providers 
 Increase/decrease session frequency 
 Add treatment services 
  
Make change to treatment goals  
(adjust standard of change) 
New goals for symptoms not improving/high 
PHQ-9 score symptoms 
 New goals missing from treatment plan 
 New goals based on client preferences 
 Set higher goals for symptom improvement 
 Set goals for sustaining symptom improvement 
  
Do nothing – client unlikely to change  
(reject standard of change) 
Change unexpected early in treatment 
  
Do nothing – PHQ-9 is inaccurate  
(reject feedback) 
PHQ-9 inaccurate for client factors/diagnoses 
 Client feelings that PHQ-9 is inaccurate 
  
Other (not captured by FIT) Tracking progress 
 Identify barriers to change 
 Review treatment goals 
 Facilitate client engagement 
 Enhance client symptom understanding 
 Identify triggers 
 Relate client symptoms to PHQ-9 scores 
 Gather additional information 
 
After sub-codes were identified, the study PI and lead research specialist completed a 
second round of coding in Atlas.ti software (Muhr, 1997) to assign sub-codes to the FIT-related 
main codes (see Table 2). The study PI and lead research specialist met to establish inter-rater 
reliability for all sub-codes assigned. 
Qualitative Analysis Procedures 
Queries were then run in Atlas.ti software (Muhr, 1997) to answer the following questions: 
a) what were the most frequently endorsed responses to FIT-related exit interview questions 
regarding how clinicians responded to feedback (questions 12-15; i.e. make a change based on 
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feedback, reject the feedback and do nothing, reject the standard of change expected, or change 
the standard); b) to what degree do clinicians report changing treatment, adjusting goals, rejecting 
the standard, or changing the standard (i.e. alignment of clinician responses with FIT); and c) how 
do clinicians with “low,” “medium,” and “high” use of MBC differ with respect to their use of 
MBC in session.  
Study 1 Results 
Participants 
 Clinicians who participated in the exit interviews (N = 16) were 100% Female, 87.50% 
Caucasian, and had an average age of 39.25 years (SD = 11.41). All participating clinicians had 
Master’s degrees, and approximately 69% were licensed mental health practitioners. The majority 
of clinicians identified Cognitive Behavioral Therapy as their primary theoretical orientation, and 
they reported a wide range of years of experience in mental health care provision (range from six 
months to 20 or more years). This sample of clinicians was generally representative of the larger 
population of clinicians across sites, as the majority of clinicians participating in the parent study 
are Female, Caucasian, and have Master’s Degrees (see Study 2 Table 10). However, there was a 
higher percentage of Cognitive Behaviorally oriented clinicians in the exit interview sample when 
compared to the broad parent R01 clinician sample. See Table 4 for additional demographic 
information for participating exit interview clinicians. 
Table 4. Demographic information for clinicians participating in exit interviews (N = 16). 
Demographic Variable Number of Clinicians (%) 
Gender  
Female 16 (100%) 
Race  
Caucasian 14 (87.50%) 
African American 1 (6.25%) 
Native American/Alaska Native 1 (6.25%) 
Ethnicity  
Non-Hispanic/Latino 16 (100%) 
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Highest Degree Obtained  
Master’s Degree 16 (100%) 
Licensure Status  
Currently Licensed 11 (68.75%) 
Not Licensed 5 (31.25%) 
Theoretical Orientation  
Interpersonal 1 (6.25%) 
Systems 1 (6.25%) 
Motivational Interviewing 2 (12.50%) 
Cognitive Behavioral  10 (62.5%) 
Other 2 (12.50%) 
Years Experience  
6-11 mos. 
1-3 yrs. 
3-5 yrs. 
5-10 yrs. 
10-20 yrs. 
>20 yrs.  
3 (18.75%) 
3 (18.75%) 
1 (6.25%) 
3 (18.75%) 
5 (31.25%) 
1 (6.25%) 
Age M= 39.25, SD = 11.41 
Range = 24-60 
 
Clinician Average MBC Adherence and Penetration 
 Participating clinicians were separated into low (N = 6), medium (N = 6), and high (N = 4) 
MBC use groups. Clinicians in the low group demonstrated infrequent use of MBC with their 
clients, with three of the six clinicians in the low group having zero adherence or penetration in 
the EHR across the 10 months post training. However, the low use clinicians who did have MBC 
data in the EHR used MBC in approximately five percent of their sessions. Medium use clinicians 
employed MBC in around 50% of their sessions, but reported that they typically did not review or 
discuss the PHQ-9 in session with clients (i.e. an average adherence score of “1” instead of “2” or 
“3.” In contrast, the high use group used MBC in approximately 75% of their sessions, and reported 
higher PHQ-9 adherence scores suggesting more frequent PHQ-9 administration, review, and/or 
discussion in session.  
Table 5. Average MBC adherence and penetration for low, medium, and high MBC use 
clinicians. 
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Clinicians Average Percent Penetration 
(SD) 
Average Adherence (SD) 
Low (N = 6) 5.41% (8.24%) 0.05 (0.05) 
Medium (N = 6) 51.22% (15.03%) 1.03 (0.31) 
High (N = 4) 72.35% (3.07%) 1.55 (0.47) 
 
Common Themes in Clinician MBC Behaviors 
 Negative feedback. When clinicians received MBC feedback that their clients were not 
progressing or were deteriorating in treatment (i.e. that the PHQ-9 scores were staying the same 
across sessions or becoming worse), they frequently endorsed gathering additional information 
from the client prior to choosing how to proceed with the PHQ-9 feedback (see Tables 6 and 7 for 
list of commonly endorsed responses). They specifically discussed having explicit conversations 
with clients to identify reasons for lack of progress. For example, some clinicians stated that, 
“Yeah, it might be other where I try to determine why that is not you know, what is going on that 
might be contributing to that [lack of progress].” Others noted: 
“If I see that somebody is really floating around the same number [on the PHQ-9], we 
would talk about, maybe, barriers to change. Sometimes those barriers are, Well, I came 
here to work on post-traumatic stress, and my depression score isn't reflecting change, but 
my anxiety is reflecting change. We might say, Okay. Well, let's continue to give you the 
PHQ-9, but really we're going to crack down on this post-traumatic, and we'll see, as we've 
done treatments that are targeting the anxiety, how that reflects in your depression."  
Clinicians also most frequently endorsed making changes to the session or treatment plan 
(i.e. FIT change behavior response), especially as a result of receiving feedback that their clients 
were deteriorating. The most common change endorsed was trying new treatment approaches, such 
as incorporating sleep hygiene, elements of Cognitive Behavioral Therapy, or motivational 
interviewing into treatment. Clinicians also discussed changing the focus of the clinical session 
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and working with the client to identify the core symptoms to be targeted in treatment. For example, 
clinicians reported using the PHQ-9 as a method for encouraging active engagement in treatment, 
noting that they would spend time in session discussing whether the client was willing to 
participate in therapy. They discussed that:  
“Just use that [the PHQ-9] during session and see if we therefore need to make a treatment 
plan [change]. Just be sure they're on board. Kind of the idea of motivational interviewing. 
Don't make changes unless they're on board and also are motivated to address it.”  
Clinicians also endorsed treatment plan changes such as adding additional services (e.g. 
medication, substance abuse treatment), adjusting the frequency of sessions, and/or changing 
treatment providers. When responding to client lack of progress, one clinician stated, “…It might 
be where we might discuss incorporating medication or now wellness coaching so [treatment] 
could vary in that way.” When responding to deterioration, another clinician noted that:  
“If they're, let's say they went from a ten to a fifteen or a sixteen I want to know what's 
going on and look at some different facets. I don't think it's maybe one thing. Maybe they 
need to change providers. Maybe they [need] to see another therapist. Maybe they need 
EMDR. Maybe it's a co-occurring. Maybe they relapsed.”  
Table 6. Five most frequently endorsed clinician responses to MBC feedback showing no 
progress. 
Theme (in order of frequency) Exemplar Quote 
Other – Gather Additional Information “But I typically will discuss it with a client, and 
say, "Why do you think that this is showing 
your scores the same? Do you feel like you've 
made progress? If not, why not?” 
 
Change Behavior – Try New Treatment 
Approaches in Session 
“…I would, like, if they came in and they, 
especially if it was a safety question at the end 
of question number nine, like, they've had a lot 
of thoughts of harming themselves or not 
wanting to wake up, then I would definitely 
change the session to include safety planning.” 
 32 
 
Change Behavior – Clinician/Client 
Identification of Session Focus 
“Maybe we just kind of slow down in some 
ways to do some symptom recognition which 
could be anger recognition or negative patterns 
of thinking or a common situation that keep 
triggering certain things.” 
 
Change Behavior – Add Treatment Services “Maybe it's adding case management. Maybe 
it's going from monthly to biweekly. Maybe 
it's going from biweekly to weekly. That's a 
hard one to say.” 
 
Change Behavior – Client Directed Treatment 
Changes 
“The whole treatment, yeah. So we might go 
back to medication, I might increase services, 
I might see them more frequently, do 
something a little different, ask them what they 
think might help.” 
 
Table 7. Five most frequently endorsed clinician responses to MBC feedback showing 
deterioration. 
Theme (in order of frequency) Exemplar Quote 
Other – Gather Additional Information “Then I guess we would, in the session we 
would probably explore. Could there be 
something going on that's contributing, like a 
situational thing?” 
Change Behavior – Try New Treatment 
Approaches in Session 
“Yes. Maybe not the treatment plan, but the 
session plan. And again, that could be the 
answer to the previous question too. Just use 
that during session and see if we therefore need 
to make a treatment plan. Just be sure they're 
on board. Kind of the idea of motivational 
interviewing. Don't make changes unless 
they're on board and also are motivated to 
address it.” 
Change Behavior – Clinician/Client 
Identification of Session Focus 
Interviewer: “Yeah I think it's the second 
option. [Changing] What you're planning to do 
in the session.” 
Clinician: “ Yeah, then that one would make 
sense.” 
Change Behavior – Add Treatment Services “If they're regressing, getting severe, then I'm 
going to have to look into other avenues. I don't 
believe that the PHQ-9 is wrong, I think at that 
time that's how they're feeling. It just goes back 
to me again exploring and see where we're at 
and if there's any changes it has made in their 
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lives. It's just, there again, addressing it and 
then if they're needing more services then I 
have to go further into their services. If it's me, 
if I'm the cause and I'm the reason why they're 
not making progress then I need to see if 
someone else can take on them, 'cause it's not 
about me it's about them. It's about trying to 
find what can help them.” 
Change Behavior – Client Directed Treatment 
Changes 
“I guess it would depend on the score. If it was 
... I think it would be up to the client as far as 
how they feel like they're doing and what they 
want to work on.” 
 
 Positive feedback. Clinicians’ responses to MBC feedback when clients were making 
progress in treatment significantly differed from responses discussed for lack of progress (see 
Table 8). Clinicians most frequently endorsed either doing nothing when they received feedback 
indicating progress (i.e. a FIT reject standard response) or setting higher goals or goals targeting 
remaining symptoms (i.e. a FIT adjust standard response). Clinicians noted ongoing monitoring 
and progress review with clients when they chose to reject the standard, stating that: 
 “If they're making the progress I'll leave things the way they are unless I see down the 
road where things are ... Where it's becoming ineffective, that either they've met these 
goals, or these goals aren't meeting all these needs, then I'll go over that.”  
Clinicians also noted the potential for setting higher goals for their clients, setting goals to 
sustain change, or collaboratively identifying new goals with the client to target remaining 
clinically significant symptoms.  They noted that: 
“So I wouldn't do anything to change the treatment, but I'd look to see if there's a phase 
two or phase three of our treatment. Whether it'd be a higher goal or whether it'd be a gap 
in between sessions to test the sustainability of their changes. Or them being able to 
maintain it.”  
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 Clinicians also reported that, “If it [symptom] was consistently improving then I would 
look towards either transitioning to new treatment goals because we had achieved previous ones.” 
They also noted that they might consider reducing the frequency of sessions, highlighting that they 
might consider, “…even transitioning to decreasing services or whatever was most appropriate for 
that client.” 
Table 8. Five most frequently endorsed clinician responses to MBC feedback showing progress. 
Theme (in order of frequency) Exemplar Quote 
Reject Standard – Do Nothing to Change 
Treatment  
“If they're making the progress I'll leave things 
the way they are unless I see down the road 
where things are...” 
 
Adjust Standard – Set Higher Goals for 
Changes in Treatment 
 
Clinician: “…We'll see if it's consistent 
overtime, and then we make changes to the 
treatment goals.” 
Interviewer: “So in that case you're 
adjusting the treatment so that they go for 
higher goals?” 
Clinician: “Mm-hmm (affirmative)” 
 
Adjust Standard – Goal Setting Based on 
Client Preferences 
“I think I would keep doing what we're doing. 
I might ask them if there's a change in goals 
they want to, that they've reached a good level 
and symptoms seem to be well in hand and 
kind of find out what they want to work on.” 
 
Change Behavior – Increase/Decrease Session 
Frequency 
“Again depending on where they are, it might 
be a recommendation to have less frequent 
sessions for example.” 
 
Adjust Standard – New Goals for Symptoms 
Remaining/Not Improving 
“I also think there's times when things get 
completely, you know, one issue that maybe 
was presented at one point is no longer an issue 
so we kind of shift to what else could be going 
on that maybe we can focus on to continue to 
enhance this person's quality of mental health 
and their life.” 
 
Alignment of Clinician MBC Behaviors with FIT 
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 As highlighted above, the FIT identifies four behavioral responses that clinicians might 
engage in following receipt of MBC feedback on client progress. They may change their behavior 
and try new treatment approaches (change behavior), adjust the standard of change and set new 
goals for symptom improvement (adjust standard), reject the standard of change as their client is 
unlikely to change (reject standard), or reject the feedback due to believing that MBC with the 
PHQ-9 does not accurately assess client symptoms (reject feedback).  
The majority of coded exit interview content aligned with the four FIT behavioral 
responses. Clinicians identified that they were most likely to change the treatment or session plan 
upon receiving feedback (changing behavior), followed by changing treatment goals (adjust 
standard). A few clinicians also reported that they would reject the standard of change and do 
nothing if they received feedback showing lack of progress or deterioration, especially early in 
treatment when change was unlikely to have occurred. Rejecting the standard of change was a 
more common response when clinicians received feedback showing progress, as many clinicians 
noted that they may not choose to make changes if the client demonstrated improvement. Very 
few clinicians reported that they would reject the feedback, highlighting reasons for rejecting 
including scores not reflecting client perception of symptom severity and the PHQ-9 not being 
accurate for certain comorbid diagnoses such as Obsessive Compulsive Disorder.   
However, clinicians also identified several approaches to responding to feedback that did 
not fit neatly within the FIT model. In specific, clinicians frequently reported using the PHQ-9 to 
gather additional information, both from the client and from the treatment plan in order to identify 
reasons for symptom change. They noted that they would engage in this information gathering 
process prior to making a decision about how to use MBC in session. Additionally, clinicians 
reported using the PHQ-9 primarily to track progress, noting that progress or lack of progress does 
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not necessarily require immediate decisions about making treatment changes. For example, 
clinicians noted that:  
“That really depends on what kind of changes have been made, and what kind of progress 
has been made, and whether it's a sustained progress or a blip. So I might wait a couple of 
sessions [before making changes].”  
Differences Among Low, Medium, and High MBC Users 
 Changing behavior. Clinicians with low, medium, and high use of MBC demonstrated 
unique patterns of MBC in-session behavior. Although clinicians most frequently endorsed 
changing behavior in session as a result of negative feedback (i.e. when compared to the other FIT 
behavioral approaches), low and medium MBC users were more likely to change their behavior 
than high MBC users. Both low and medium MBC users endorsed trying new treatment 
approaches in session when noticing lack of treatment progress more frequently than high users. 
In fact, low and medium use clinicians were the only clinicians to endorse using the PHQ-9 as a 
tool to enhance client treatment engagement in session or to add treatment services.   
Low users were also more likely than either high or medium users to report adjusting the 
frequency of sessions following receipt of negative MBC feedback. In comparison, medium MBC 
users were more likely to use MBC to encourage collaborative identification of what to focus on 
in session. Although high MBC users were less likely to report changing their behavior, those who 
did noted that they used MBC to guide the session focus in accordance with client preferences. 
There were no significant differences among low, medium, and high users regarding behavior 
change when they received positive feedback that the client was improving.    
 Adjust standard. There were very few differences among low, medium, and high use 
clinicians in their decisions to change treatment goals (i.e. adjusting the standard of change) as a 
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result of receiving MBC feedback. Of those who did endorse changing goals, low use clinicians 
were the only clinicians to endorse that they would set higher goals or goals related to sustaining 
symptom improvement when they received feedback that their clients were improving (i.e. positive 
feedback). In contrast, both high and medium use clinicians were more likely than low use 
clinicians to discuss setting new goals in treatment based on client preferences or setting new goals 
for symptoms not yet been addressed when MBC scores indicated lack of progress or deterioration 
(i.e. negative feedback).  
 Reject standard. Medium use clinicians were more likely than low or high use clinicians 
to endorse rejecting the standard and not making changes in treatment when MBC indicated that 
the client was improving (i.e. positive feedback). Despite endorsing that they would continue with 
treatment as usual, medium use clinicians noted that they would engage in ongoing progress 
monitoring with the PHQ-9 to verify that changes to treatment were not needed. For example, they 
noted that:  
“If they're making the progress I'll leave things the way they are unless I see down the road 
where things are ... Where it's [treatment’s] becoming ineffective, that either they've met 
these goals, or these goals aren't meeting all these needs, then I'll go over that.” 
Very few clinicians endorsed rejecting the standard of change because the client was 
unlikely to improve after receiving scores showing no progress or deterioration (i.e. negative 
feedback). Only one medium and one high use clinician noted that significant change may not 
occur early in treatment, stating that:  
“…I wouldn't make any changes just because I'm kind of looking at ... It's been two weeks, 
this person may not change. If somebody's score continues to be consistently high and I 
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really think they're making efforts, then certainly I would use that to look at the goals, look 
at what we're doing and see how we need to adjust treatment.” 
Reject feedback. Only three (two medium and one low use clinician) of the 16 
participating clinicians reported instances of rejecting feedback due to believing that the PHQ-9 
was inaccurate. The medium use clinicians reported that they might reject negative feedback due 
to the PHQ-9 being inaccurate for clients who reported consistently high scores across treatment 
or for clients with particular diagnoses not assessed by the PHQ-9, such as Asperger’s or Obsessive 
Compulsive Disorder. The low use clinician reported that she may choose to reject negative 
feedback if the client feels the PHQ-9 does not show the client’s true progress, stating that, 
“Sometimes the clients feel like that's [the PHQ-9’s] pretty inaccurate, I have made progress.” 
None of the clinicians reported that they would reject the feedback if they received positive 
feedback indicating client improvement.  
Other. There were no differences among low, medium, and high use clinicians in using 
MBC to gather additional information about the reasons for symptom change prior to making 
treatment changes or in using MBC to track treatment progress over time.  
Study 1 Discussion 
Results from this qualitative study are the first, to our knowledge, to explore the utility of 
the FIT for capturing clinician approaches to using MBC in session. Outcomes of the clinician exit 
interviews largely supported initial hypotheses, as clinicians noted that their responses to receiving 
positive or negative feedback from the PHQ-9 commonly aligned with the FIT outcomes (i.e. 
changing behavior, adjusting standard, rejecting standard, or rejecting feedback). As expected, 
however, some clinicians did report diverging from the FIT in two key ways. For example, some 
clinicians noted that they would not engage in any of the responses after receiving negative 
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feedback, instead using the PHQ-9 as an opportunity to either gather additional information about 
reasons for symptom change or to simply track progress without making treatment changes.  
It is important to note that it may be quite challenging for community clinicians to identify 
how much depression symptom change should realistically occur in therapy (i.e. the standard of 
change). Clinicians in the community work with clients with high symptom severity and 
significant comorbid diagnoses, two predictors of low treatment response (Jarrett, Eaves, 
Grannemann, & Rush, 1991). Literature also suggests that community clients demonstrate slower 
rates of symptom change and higher rates of deterioration when compared to clients in managed 
care settings (Warren, Nelson, Mondragon, Baldwin, & Burlingame, 2010). Community clients 
may also present with substantial environmental stressors (e.g. poverty) that may have differential 
impacts on depressive symptoms from session to session (Harper et al., 2015). As a result, 
clinicians are charged with the task of gathering information about both the standard of change to 
expect from each of their clients and the potential for variation in this change due to weekly crises 
and ongoing stressors. These factors may explain clinicians’ tendency to gather additional 
information from their clients prior to selecting one of the FIT behavioral responses, as changes 
may or may not be warranted depending on the consistency of clients’ patterns of symptom change. 
Additional research is warranted to explore expected PHQ-9 standards of change in community 
mental health settings and the degree to which this standard is influenced by client factors.  
It is also important to highlight that FIT is a theory guiding individual behavior change; 
therefore it may not be the optimal theory to capture both clinician and client behavioral responses 
to feedback. Given evidence suggesting that MBC is most effective when feedback is provided to 
both the clinician and the client, it is likely crucial to capture client responses to receiving feedback. 
Even clinicians’ best efforts to make behavioral changes in treatment may be met with client 
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resistance or low engagement, ultimately limiting the effectiveness of treatment (Westra & Dozois, 
2006). In fact, a few clinicians noted in the exit interviews that they would need to have clients on 
board with changes prior to moving forward in treatment and that some of their clients felt the 
MBC feedback was inaccurate. Future research should focus on capturing both clinician and client 
responses to feedback, both to test the appropriateness of FIT for capturing the array of responses 
and to identify the impact of various clinician-client dyad feedback responses on depression 
symptom change. 
There were also substantial differences in responses among “low,” “medium,” and “high” 
MBC users despite general alignment of responses with the FIT model. Most interesting was the 
outcome that low and medium clinicians were more likely to make changes to the treatment or 
session plan as a result of feedback showing lack of progress or clinical deterioration. One potential 
explanation for this finding is that low and medium use clinicians may be more likely to use MBC 
as a tool for guiding treatment changes more generally, while high use clinicians may strategically 
use MBC to make changes only with clients demonstrating lack of progress. Clinicians may also 
have over-reported their use of behavior change strategies, as the exit interviews required them to 
retrospectively report on their use of MBC and clinicians are vulnerable to over-reporting their use 
of EBPs (Brosan, Reynolds, & Moore, 2008; Pignotti & Thyer, 2012). Additional research is 
needed to explore differences in responses to feedback among clinicians with unique patterns of 
MBC use. Gaining additional insight into these differences may enable a better understanding of 
how much MBC is required to achieve symptom change as well as how varying MBC use levels 
feedback responses may interact to produce differential outcomes in psychotherapy for depression. 
Limitations  
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Outcomes of this qualitative study have several limitations that should be noted. First, the 
interviews that were coded for this study took place 10 months after clinicians received initial 
MBC training. The exit interviews asked clinicians to self-report on their typical responses to MBC 
feedback without a specific timeframe or client in mind. This recall process may have resulted in 
biased or inaccurate responses, as clinicians may be thinking of different timeframes (i.e. MBC 
last week, last month, etc.) and often over-report their use and competence in evidence-based 
practices such as MBC (Brosan et al., 2008; Pignotti & Thyer, 2012). Second, three of the 16 
clinicians who participated in the exit interviews did not have any adherence or penetration data 
pulled from the EHR and were therefore categorized as low use clinicians. However, all three 
clinicians indicated MBC use in their exit interviews, suggesting that the EHR data may not have 
captured the scope of their use with clients and the low use categorization may not have been 
appropriate. Third, as with most qualitative work, the sample size of this study was relatively small, 
and this qualitative analysis represents only 16 clinicians treating depression across six community 
mental health clinics. The responses of this limited sample size of clinicians may not generalize to 
community mental health clinicians more broadly.  
Finally, it is important to note that as with all qualitative analyses, the data presented herein 
are prone to subjectivity and additional research may be needed using quantitative (i.e. clinician 
surveys) or mixed methods approaches to further evaluate the utility of the FIT. While a reflexive 
team analysis approach was employed to limit the subjective interpretation of clinician exit 
interview responses, the conversational interview data used in this study were vulnerable to the 
preconceptions and interpretations of the coding team. Despite these limitations, the qualitative 
design of this study allowed for a richer and more nuanced exploration of themes not generally 
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possible with other data collection techniques, including the contextualization of findings using 
participants’ own words.  
Conclusions 
 In summary, clinicians generally employed MBC in session in line with FIT, suggesting 
that the FIT is valid for use in categorizing most behavioral responses to feedback in 
psychotherapy. Clinicians were most likely to change the treatment or session plan as a result of 
MBC showing lack of progress or deterioration. They were likely to continue with treatment as 
usual when MBC showed progress. However, clinicians also endorsed using MBC as an 
opportunity to gather additional information from their clients and track progress over several 
sessions prior to proceeding with treatment changes. This deviation from FIT highlights the 
complexities of deciding on a standard of symptom change and choosing how to proceed with 
complex community mental health clients. Results from this study have key implications for 
understanding clinicians’ typical in-session responses to MBC feedback, prompting further 
exploration of the utility of the FIT model for MBC in psychotherapy for depression, and 
ultimately identifying additional putative mechanisms of change of MBC. 
Chapter 2: Study 2 Introduction 
 Limited research has explored the degree to which clinicians choose to administer, review, 
and discuss MBC with clients in session, i.e. deliver MBC with fidelity. Psychotherapy fidelity 
assessment is frequently employed to ensure that EBPs are applied in session according to the 
guidelines that established them as evidence-based. Fidelity consists of three elements: treatment 
adherence, competence, and differentiation (Schoenwald et al., 2011). Adherence refers to the 
degree to which clinicians use an intervention like MBC as prescribed, while competence refers to 
the skill with which the clinician employs the intervention. Finally, differentiation refers to the 
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degree to which an intervention can be identified as unique from other interventions (Schoenwald 
et al., 2011). Fidelity evaluation has become a key element of implementation studies that have 
sought to better understand the degree to which EBPs may be applied flexibly while maintaining 
their outcome enhancing effects (Kendall & Beidas, 2007). Given the complex nature of 
community mental health systems, many efforts to implement EBPs like MBC require substantial 
adaptation and tailoring to address contextual barriers and encourage use with fidelity.  
 There are numerous barriers to implementation that have been highlighted in the extant 
literature that may explain variability in clinician fidelity to MBC. These barriers often exist at 
both the organizational (i.e. clinic) and individual levels. At the organizational level, variable 
implementation of EBPs like MBC may be predicted by time limitations, low availability of 
resources, poor morale among staff, and norms among both leadership and clinicians that do not 
favor MBC use (Brunette et al., 2008; Pogoda, Cramer, Rosenheck, & Resnick, 2011). For 
example, specific barriers such as minimal availability of supervision, high productivity 
requirements, and short clinical sessions may limit perceptions of the utility of MBC, and may 
even prevent use completely (Scott & Lewis, in prep). In addition, low morale among staff has 
been linked to high turnover rates across mental health organizations, making it even more difficult 
to maintain a clinician workforce that is consistently trained and supervised in MBC application 
(Beidas et al., 2016; Glisson et al., 2008; McHugh & Barlow, 2010; Woltmann et al., 2008).  
 Many individual-level implementation barriers have also been established that predict 
variable MBC implementation. These individual-level barriers include clinicians’ negative 
attitudes about MBC, perception of other clinicians’ disapproval of novel practices, lack of 
knowledge, and need for individual training and supervision  (Aarons, 2004; Aarons, Ehrhart, 
Farahnak, & Sklar, 2014; Beidas et al., 2015; Sadeghi-Bazargani, Tabrizi, & Azami-Aghdash, 
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2014). Community clinicians may also be especially vulnerable to concerns regarding the 
appropriateness of MBC given the complexity of their clients (Mitchell, 2011). For example, a few 
clinicians noted that they may reject the validity of MBC for clients with multiple diagnoses in 
Study 1 above. Finally, clinician training background and years of experience may also predict 
willingness to implement MBC. Previous literature suggests that clinicians with more years of 
experience may have received less training in EBPs, may have more negative attitudes, and may 
be less open to novel practices (Aarons, 2004; Beidas & Kendall, 2010; Stewart et al., 2012). Other 
studies also suggest that clinician age (Aarons, 2004; Beidas et al., 2015), gender (Beidas et al., 
2015), and theoretical orientation (Nelson & Steele, 2007) may lead to more or less use of EBPs 
such as MBC.  
As a result of these barriers, MBC application and fidelity in the community may vary 
significantly from the studies that established MBC as effective (see General Introduction). Even 
though it is a relatively less complex intervention than multifaceted treatments like Cognitive 
Behavioral Therapy (Beck, 2011), MBC has been variably applied across settings. Beyond the 
organizational and invidual barriers highlighted above, variation may also be due to the fact that 
MBC may take on unique formats, as it has been applied using electronic tools to help psychiatrists 
make decisions about medication management (Trivedi et al., 2007), using technology to enhance 
treatment in a community substance abuse clinic (Crits-Christoph et al., 2012), and using paper-
and-pencil self report measures to enhance depression care in community behavioral health clinics 
(Lewis et al., 2015).  
Despite documentation of variable MBC application, no efforts to our knowledge have  
characterized patterns of use and the degree to which these patterns map on to MBC adherence 
recommendations established in the literature. It is important to not only understand the degree to 
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which clinician patterns of adherence deviate from recommendations established by the field (i.e. 
administering a measure, reviewing the score trajectory, and discussing with client at every 
session) but also to identify the characteristics of community clinicians with distinct patterns of 
MBC use. Gaining a better understanding of these characteristics may enable the identification of 
clinicians with high likelihood of MBC implementation who may be leveraged as champions and 
change agents within community mental health settings (Kitson, Harvey, & McCormack, 1998). 
In addition, understanding the impact of different patterns of MBC adherence on depression 
symptoms may enable the identification of the dosage of MBC required to maximize symptom 
change. 
Evaluating MBC Adherence Patterns 
Although variability in MBC adherence has been reported in the literature using 
retrospective clinician self-report or measures of implementation (Bickman et al., 2016; Connolly 
Gibbons et al., 2015; Whipple et al., 2003), it is possible that there are unexplored reliable and 
observable patterns of MBC use that can characterize subpopulations of clinicians over time. 
Single timepoint and variable-centered approaches to exploring how clinicians use MBC can be 
useful for characterizing adherence or identifying the degree to which MBC adherence is 
associated with positive outcomes. However, these variable centered approaches assume 
homogeneity among the population of clinicians employing MBC (Muthén & Muthén, 2000). As 
noted above, clinician characteristics may differentially impact MBC adherence, resulting in 
unique patterns of MBC use over time that may be missed through more traditional variable-
centered approaches. Growth mixture modeling (GMM) is a person-centered analytic approach 
that allows for identification of unique subpopulations of individuals with common patterns of 
change over time (Jung & Wickrama, 2008; B. Muthén & Muthén, 2000; Wickrama, Lee, O’Neal, 
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& Lorenz, 2016). It is an approach that combines conventional growth modeling approaches with 
latent class analysis in order to identify classes of individuals, explore unique growth curves over 
time for each class, and estimate within class-variation through growth factor variances for each 
class (Muthén & Muthén, 2000). GMM also enables the exploration of predictors of class 
membership, thereby identifying the individuals who may be more or less likely to demonstrate a 
particular pattern of change. GMM may be especially well suited for identifying classes of 
clinicians who use MBC differently in community mental health settings. 
GMM techniques have previously been employed in the literature to elucidate patterns of 
symptom presentation, symptom change over time, and predictors of these patterns in mental 
health treatment (Lutz, Stulz, & Köck, 2009; Yaroslavsky, Pettit, Lewinsohn, Seeley, & Roberts, 
2013). GMM approaches have been employed to identify classes of individuals with high 
likelihood of substance dependence across their lifetimes (Muthén & Muthén, 2000), classifying 
individuals as normative drinkers, very heavy drinkers that decreased over time, heavy drinkers 
that decreased over time, and increased heavy drinkers over time. GMM approaches have also 
been explored to identify classes of individuals with unique response rates to depression 
medication (Muthén, Brown, Leuchter, & Hunter, 2008), to predict academic outcomes due to 
patterns in child caregiver sensitivity (Hirsh-Pasek & Burchinal, 2006), and to evaluate risk factors 
for poor school adjustment among homosexual youth (Murdock & Bolch, 2005). 
For example, data from the Treatment for Adolescent Depression Study (TADS; Team, 
2003) was subjected to GMM to identify three class of adolescents with unique symptom change 
trajectories: a high severity with early improvement class; a high severity with limited 
improvement class; and a moderate severity with late improvement class. The high severity with 
early improvement class was more likely to have high levels of baseline hopelessness and suicidal 
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ideation when compared to other classes, providing crucial information that may guide 
identification of clients most likely to demonstrate early clinically significant change in 
psychotherapy (Scott, Lewis, & Marti, under review). 
Despite GMM’s power for evaluating unique individual patterns of symptom change and 
predictors of these patterns, GMM has been underutilized as a tool to evaluate clinician 
implementation of EBPs like MBC. A single study identified in the literature employed GMM for 
evaluating the impact of different levels of supervision for teachers on the implementation of a 
novel evidence-based teaching strategy in the classroom (Pas et al., 2015). Outcomes of the GMM 
identified three classes of teachers who received low, moderate, and high levels of support to 
employ an evidence-based teaching strategy. Teachers in the high and increasing support class 
demonstrated increased implementation of the teaching strategy, while low support teachers had 
the lowest implementation. Although these findings reflect patterns related to support received 
rather than EBP implementation, they highlight the potential utility of GMM for identifying 
relations among unique classes of individuals and EBP use.   
The Present Study 
In sum, GMM may be an important tool for identifying how clinicians use MBC, how 
different use patterns impact clinical outcomes, and which clinicians are most likely to implement 
MBC with adherence (i.e. predictors of class membership). The present study will serve to identify 
patterns and trajectories of clinician adherence and in-session MBC behaviors across treatment 
(Study 2 aim). Such procedures may provide insight into the the dosage of MBC needed to promote 
depression symptom change. The present study sought to leverage GMM to specifically identify 
patterns and trajectories of clinician adherence and in-session MBC behaviors across treatment, as 
well as predictors of these patterns and their impact on depression outcomes. 
 48 
Hypotheses  
It was anticipated that the GMM procedure would reveal three unobserved groups of 
clinicians with unique patterns of MBC use (H1). These three groups would be representative of 
high MBC adherence users, medium MBC adherence users, and low MBC adherence users. As 
discussed in Roger’s theory on diffusion of innovations, the high MBC users would represent EBP 
early adopters who were experienced EBP users and therefore quick to accept and use MBC 
following training (Kitson et al., 1998; Rogers, 2010). In contrast, medium and low users would 
represent clinicians in the early/late majority and laggard groups, two groups taking longer to begin 
MBC implementation. Given the literature suggesting that diffusion of innovations occurs slowly 
over time with training and ongoing supervision of implementation (Rogers, 2010), it is anticipated 
that all three groups will demonstrate a slow increase in MBC adherence due to receipt of ongoing 
consultation or implementation team meetings across five months post training (Lewis et al., 
2015). Some clinicians may also begin administering the PHQ-9 following training (adherence 
score of “1”), but may not review and discuss the PHQ-9 (adherence score of “3”) until later in the 
five-month active implementation period while others may start with administering and reviewing 
and later increase to more frequent discussion (H2). Finally, it is also hypothesized that therapists 
who have fewer years of experience will be more likely to be members of the “high adherence” 
group (H3), given literature suggesting that individual-level barriers such as years of experience 
may impact MBC implementation (Aarons, 2004; Beidas & Kendall, 2010).   
Study 2 Methods 
Participants 
All enrolled study clinicians in the parent R01 who provided at least one adherence 
observation during their five month active implementation period across the 10 sites were included 
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in the analysis (N = 92). Given the dynamic cohort-based design of the study, clinicians from the 
different sites had unique timeframes for their active implementation (see Table 9). 
Table 9. Timeline for 5-month active implementation for each site. 
 Month 0 
(month of 
training) 
Month 1 Month 2 Month 3 Month 4 Month 5 
Site 1 (C1) 7/2015 8/2015 9/2015 10/2015 11/2015 12/2015 
Site 2 (C1) 7/2015 8/2015 9/2015 10/2015 11/2015 12/2015 
Site 3 (C2) 12/2015 1/2016 2/2016 3/2016 4/2016 5/2016 
Site 4 (C2) 12/2015 1/2016 2/2016 3/2016 4/2016 5/2016 
Site 5 (C2) 12/2015 1/2016 2/2016 3/2016 4/2016 5/2016 
Site 6 (C2) 1/2016 2/2016 3/2016 4/2016 5/2016 6/2016 
Site 7 (C3) 5/2016 6/2016 7/2016 8/2016 9/2016 10/2016 
Site 8 (C3) 5/2016 6/2016 7/2016 8/2016 9/2016 10/2016 
Site 9 (C3) 5/2016 6/2016 7/2016 8/2016 9/2016 10/2016 
Site 10 (C3) 5/2016 6/2016 7/2016 8/2016 9/2016 10/2016 
Note. C1= Cohort 1, C2 = Cohort 2, C3 = Cohort 3. 
 
Measures 
Average clinician adherence. The primary measure for this study was average monthly 
therapist adherence to MBC measured across the five-month active implementation period (i.e. 
workshop training through five months post-training, see Table 9). This method was selected in 
order to obtain a measure of adherence at the clinician level, as the goal of the GMM analysis to 
be explored in the present study was to identify classes of clinicians. Client’s session-by-session 
adherence scores ranging from “0” (i.e. no PHQ-9 completion) to “3” (i.e. PHQ-9 completion, 
review, and discussion in session) were pulled from the EHR. The average monthly adherence 
score for each clinician was then computed by taking the average of the adherence scores for each 
clinician across all of their depression pathway clients in a specific month (i.e. clinician adherence 
scores of 0, 2, and 3 in Month 3 would be averaged to obtain a Month 3 score of 1.67).  
Covariates. Predictors of GMM class membership included clinician age, race, theoretical 
orientation, and years of experience providing mental health care. These covariates were 
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considered as time invariant covariates as they were measured only at baseline for all clinicians. 
All of these predictor variables were selected given evidence suggesting their role in clinicians’ 
openness and ability to implement novel EBPs like MBC (Beidas et al., 2015; Nakamura, Higa-
McMillan, Okamura, & Shimabukuro, 2011; Nelson & Steele, 2007; Stewart et al., 2012). Race 
(white/non-white), theoretical orientation (Cognitive Behavioral/non-Cognitive Behavioral 
Orientation), and years of experience (less than five years/greater than five years)  were included 
in the models as dichotomous variables, with a reference group of white for race, Cognitive 
Behavioral Orientation for theoretical orientation, and greater than five years for years experience.  
Distal outcome variables. Average baseline and Month 5 PHQ-9 scores were also 
included in the analysis to identify whether class membership had an impact on client depression 
symptom change at the end of the active implementation period (i.e. Month 5). This method was 
again selected in order to have PHQ-9 symptom outcome data at the clinician level. To calculate 
average monthly clinician PHQ-9 scores, depression pathway clients’ session-by-session PHQ-9 
scores were first pulled from the EHR. This data was supplemented with baseline and Week 12 
PHQ-9 scores collected for all enrolled clients by study research staff in order to maximize the 
data included in generating the average PHQ-9 scores. Average baseline PHQ-9 scores were 
computed two ways for the analysis: a) by taking the average PHQ-9 score of both new (i.e. clients 
who had started therapy after clinician MBC training) and ongoing depression pathway clients (i.e. 
clients who had started therapy prior to clinician MBC training) seen by a clinician during the 
month in which the clinician received MBC workshop training (i.e. Month 0); and b) by taking the 
average PHQ-9 scores for only new clients at Month 0. For example, if Client A had scores of 5 
and 10 and Client B had a score of 20 during the month the clinician received MBC training, the 
clinician would receive an average client baseline PHQ-9 score of 11.67. Average Month 5 PHQ-
 51 
9 scores were also computed two ways by taking the average PHQ-9 scores of new and ongoing 
depression pathway clients seen by each clinician during the fifth month of active implementation 
as well as by taking the average PHQ-9 for only new clients. 
Nesting variables and design effects. Given that clinicians were nested within sites, site 
was explored as a potential nesting variable to be accounted for in the analyses. Intra-class 
correlation values were computed to evaluate the impact of site on the variance in clinician 
adherence. Design effect scores were then calculated using the formula DEFF = 1 + (nc -1)ICC, 
where nc is the average cluster size (i.e. average number of clinicians per site). Per the 
recommendations of Muthen & Satorra (1995), design effects greater than two were used to 
determine the need to account for nesting in all GMMs. 
Growth Mixture Modeling Analyses 
Average monthly adherence scores from the active implementation period (i.e. first five 
months post workshop training) were modeled using a four-step procedure with each step adding 
additional parameters, thereby increasing model complexity. Models were explored in the 
following order to identify classes of clinicians with unique trajectories of MBC adherence over 
time: a) basic growth model, b)  Latent Class Growth Analysis (LCGA), c) Growth Mixture Model 
with class invariant variances and covariances (GMM-CI), and d) Growth Mixture Model with 
class variant variances and covariances (GMM-CV). This four-step procedure followed 
recommendations by Wickrama and colleagues (2016). 
First, a basic growth model was fit to the data to identify the presence of changes in average 
clinician adherence over the five-month active implementation period. A quadratic term was then 
added to the model and the fit compared to the linear model to identify the optimal shape of the 
growth curve. Second, a series of Latent Class Growth Analyses (LCGA) were run to compare k 
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= 1 to k = 5 class models (i.e. models with total number of classes varying from 1 to 5) per 
recommendations from Wickrama et al. (2016). The LCGA is a restricted GMM model that 
enables the identification of unique mean intercepts and slopes across classes but fixes all within 
class variances to zero. Fixing the within class variances assumes that all trajectories of change are 
homogenous within each class and only estimates between class variances in growth factors 
(Berlin, Parra, & Williams, 2014). The LCGA approach is identified as a preferred second step in 
the model building procedure as it enables the identification of classes with lower computational 
burden than GMM (Wickrama et al., 2016).  
Third, GMM-CI models were explored for k = 1 to k = 5 classes with invariant variances 
and covariances. The GMM-CI models allow for means and growth factors to be unique within 
classes, but holds residual variances and covariances of the growth factors equal across classes. 
Finally, GMM-CV models were explored for k = 1 to k = 5 classes to allow for the estimation of 
class variant variances and covariances. 
All GMM models were fit using maximum likelihood estimation with robust standard 
errors in order to use all available data given the presence of missing data within the sample 
(Graham, 2009). The Bayes Information Criterion (BIC), entropy values, and average class 
probabilities were the primary criteria for determining the optimal number of latent classes of 
clinicians (Enders & Tofighi, 2008; Nylund, Asparouhov, & Muthén, 2007). The Bootstrap 
Likelihood Ratio Test (BLRT) could not be employed in this analysis due to inability to calculate 
BLRT values with nested, imputed data in Mplus statistical software. Per recommendations by 
Nylund and colleagues (2007), lower BIC values and higher entropy values identify better model 
fit. It is also optimal for all average class probabilities to be greater than 0.80, indicating a high 
probability of correct classification of individuals (Geiser, 2012).  
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After determining the appropriateness of GMM via the basic growth model, model fit 
indices for the LCGA, GMM-CI, and GMM-CV models with k = 1 to k = 5 classes were compared 
to identify models that minimized BIC, maximized entropy, and had average class probabilities 
above 0.80. Given the small sample size of clinicians being modeled (N = 92), the model selection 
procedure also sought to identify a model with classes with adequate prevalence (i.e. adequate 
number of clinicians in each class), as small class prevalence with a small sample size may not 
represent a true class (Dziak, Lanza, & Tan, 2014). Given the limited literature informing the 
selection of classes based on class prevalence, decisions regarding retention of classes with small 
membership were based on theory. For example, if fewer than 10% of clinicians fell into a class 
with a unique trajectory of adherence over time, the class was retained in the model to account for 
this unique variation. However, if the class membership was below 10% and the trajectory of 
change was not unique (i.e. similar slope estimates), the k-1 (i.e. the model with one less class) 
model was selected to maximize parsimony.  
Three-Step Approach for Incorporating Predictors and Distal Outcomes 
The three-step maximum likelihood (ML) approach for regressing latent classes on 
independent variables (i.e. predictors of class membership such as age and years experience) and 
distal outcomes (i.e. Month 5 PHQ-9 scores; Bakk, Tekle, & Vermunt, 2013; Vermunt, 2010) was 
then employed to explore differences across classes. The first step in the three-step approach 
involved identifying the best-fit model (see above). In the second step, a likely class membership 
variable was calculated from the best-fit model results. Third, two separate analyses were run to 
assess covariate predictors of class membership and differences between classes in baseline and 
Month 5 PHQ-9 symptom scores. The likely class membership variable (a categorical dependent 
variable) was first regressed on covariates (i.e. clinician age, gender, race, theoretical orientation, 
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years of experience with therapy) using multiple logistic regression. Then, Wald’s Chi-squared 
tests were assessed to test equality of mean baseline and Month 5 PHQ-9 scores among classes 
(Asparouhov & Muthén, 2013; Bakk et al., 2013). Overall, this three-step approach identified the 
number of different clinician groups (i.e. classes) with unique MBC adherence trajectories, 
assigned each clinician (N = 92) to a class, and explored whether predictor variables such as age 
and years experience and depression symptom outcomes differed among clinicians with unique 
patterns of MBC adherence. 
Convergence Issues and Local Maxima 
  
 In order to minimize convergence issues and the presence of local maxima, common issues 
in GMM analyses with small sample sizes (Muthén et al., 2008), a high number of random starting 
values were used along with the OPTSEED procedure in Mplus to ensure the identification of 
global maxima and replication of the largest loglikelihood values across all models. (Wickrama et 
al., 2016). Random starts were selected based on the complexity of the model and ranged from 
500 to 2000. After each model was run in Mplus, two additional OPTSEED runs were explored 
for each model using the two seed values with the best loglikelihood. This procedure was 
completed to ensure that parameter estimates were associated with the single largest loglikelihood 
value (i.e. the global maximum value) per recommendations from Wickrama and colleagues 
(2016).  
Study 2 Results 
Participants 
 The majority of clinicians (N = 92) were female (81.52%), Caucasian (83.70%), and non-
Hispanic or Latino (97.83%). Most of the clinicians had Master’s Degrees (91.30%), and more 
than half were currently licensed (60.87%) at the time of baseline data collection. Many also 
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endorsed a primary theoretical orientation of Motivational Interviewing (48.91%), with others 
commonly identifying as eclectic therapists (18.48%). Clinicians were a wide range of ages (M = 
44.34, SD = 12.59) and had a wide range of years of experience providing mental health treatment 
(66.30% with five or more years of experience).  
Table 10. Demographic information for clinicians used in GMM analysis (N=92). 
Demographic Variable Number of Clinicians (%) 
Gender  
Female 75   (81.52%) 
Male 15   (16.30%) 
Missing 2   (2.17%) 
Race  
Caucasian 77  (83.70%) 
African American 9   (9.78%) 
Asian 1   (1.09%) 
Native American/Alaska Native 2   (2.17%) 
More than one race 1   (1.09%) 
Missing 2   (2.17%) 
Ethnicity  
Non-Hispanic/Latino 90  (97.83%) 
Missing 2  (2.17%) 
Highest Degree Obtained  
Bachelor’s Degree 2   (2.17%) 
Master’s Degree 84  (91.30%) 
Doctoral Degree 3   (3.26%) 
Other 1   (1.09%) 
Missing 2   (2.17%) 
Licensure Status  
Currently Licensed 56  (60.87%) 
Not Licensed 34  (36.96%) 
Missing 2   (2.17%) 
Theoretical Orientation  
Behavioral Modification 2   (2.17%) 
Integrative 5   (5.43%) 
Eclectic 17  (18.48%) 
Biological/Medical 5   (5.43%) 
Interpersonal 3   (3.26%) 
Systems 6   (6.52%) 
Motivational Interviewing 45  (48.91%) 
Cognitive Behavioral  2   (2.17%) 
Psychodynamic 2   (2.17%) 
Missing 5   (5.43%) 
Years Experience  
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0-6 mos. 2  (2.17%) 
6-11 mos. 
1-3 yrs. 
3-5 yrs. 
5-10 yrs. 
10-20 yrs. 
>20 yrs. 
Missing  
6  (6.52%) 
17  (18.48%) 
6  (6.52%) 
17  (18.48%) 
25  (27.17%) 
16  (17.39%) 
3  (3.26%) 
Age M = 44.34 (SD = 12.59, Range = 24-70) 
 
Missing data – Monthly Adherence 
 Fifty-nine of the 151 clinicians enrolled in the parent R01 study had missing data for all 
monthly average adherence time-points (baseline to Month 5), resulting in a final sample of 92 
clinicians with at least one observation across time points. Across time points, 29 adherence 
observations (31.5%) were missing at Month 0 (i.e. baseline), 15 (16.3%) at Month 1, 16 (17.4%) 
at Month 2, 13 (14.1%) at Month 3, 14 (15.2%) at Month 4, and 13 (14.1%) at Month 5. Monthly 
adherence data were fit using maximum likelihood estimation with robust standard errors to 
account for these missing observations and use all available data points, therefore imputation was 
not performed on these data  (Graham, 2009). 
Missing data – Predictors 
For the clinician predictor variables, two out of 92 (2.17%) observations were missing for 
race, two for gender (2.17%), two for age (2.17%), five for theoretical orientation (5.43%), and 
three for years experience (3.26%). Multiple imputation was employed to account for all missing 
predictor values (see imputation procedure in General Methods section). 
Missing Data – Distal Outcome 
 For the distal outcomes, 64 out of 92 (69.57%) observations were missing for average 
baseline PHQ-9 scores, while 44 observations were missing for average Month 5 PHQ-9 scores 
(47.83%). Multiple imputation was employed to account for missing distal outcome values, 
 57 
however the large percentage of missing data for both baseline and Month 5 average PHQ-9 scores 
was considered in interpretation of analyses.  
Data Nesting 
The study design involved the clustering of clients within sites, therefore site differences 
in adherence have the potential to contribute significant variability to the growth mixture modeling 
approach. An empty random intercept regression model was explored to determine the impact of 
site on adherence, identify the intra-class correlation values for all time points (i.e. percentage of 
variance in adherence accounted for by site), and test the need for clustering to be accounted for 
in all models. The random intercept model identified ICC’s consistently above zero for all time 
points, suggesting a range of 12.1% to 33.9% of variance in clinician adherence is accounted for 
by site. 
  
All design effect values were less than 2.0 except for T2 (i.e. average adherence in Month 
two post training). The design effect value for T2 suggests a need for multilevel modeling, as it is 
likely that ignoring the impact of nesting on the model will underestimate model standard errors. 
As a result, nested models will be explored accounting for the nesting of clinicians within site. 
However, given the small sample size of clinicians (N = 92) and the significant computation burden 
of multilevel modeling, the multilevel models had a number of convergence problems and 
limitations highlighted below. 
Table 11. Intra-class correlations for the random intercept regression model including site as 
nesting variable. 
T0           0.150       T3           0.171       
T1           0.139       T4           0.194       
T2           0.339 T5           0.121 
Table 12. Design effect values for all time points to determine nesting. 
T0           1.38 T3           1.57     
T1           1.28      T4           1.78       
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Data Distribution 
All monthly average adherence score values were highly skewed to the right (see Figure 1
for frequency distribution and Table 13 for skew statistics).  All Kurtosis values were positive 
indicating that all monthly average adherence scores had heavy tails, also known as a leptokurtic 
distribution. These skew and kurtosis values suggest the presence of many “0” adherence values 
in the data set. Indeed, 34 (37.0%) adherence observations had a score of “0” for Month 0 (i.e. 
baseline), 44 (47.8%) for Month 1, 28 (30.4%) for Month 2, 25 (27.2%) for Month 3, 29 (31.5%) 
for Month 4, and 27 (29.3%) for Month 5. 
  
T2           3.12 T5           1.11 
Table 13. Skewness statistics for monthly average adherence scores. 
Month 0           1.69 Month 3           0.74     
Month 1           1.55      Month 4           0.94       
Month 2           1.44 Month 5           1.33 
Table 14. Kurtosis statistics for monthly average adherence scores. 
Month 0           5.56 Month 3           2.53     
Month 1           4.57      Month 4           3.05       
Month 2           4.32 Month 5           4.22 
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Figure 1. Histograms of distributions of average monthly adherence scores for clinicians. 
Average MBC Adherence Over Time 
Average clinician MBC adherence scores were quite low and ranged from 0.41 at baseline 
to 0.61 at Month 5 (see Table 15 below). However, standard deviation values suggest variability 
in monthly MBC adherence, therefore person-centered analyses were appropriate to identify 
patterns of MBC adherence that differ among clinicians.  
Table 15. Average clinician MBC adherence scores for all clinicians (N=92) across five months 
post training. 
Month Mean (SD) 
0 (baseline) 0.41 (0.63) 
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1 0.35 (0.53) 
2 0.57 (0.74) 
3 0.68 (0.69) 
4 0.63 (0.67) 
5 0.61 (0.71) 
 
Correlations – PHQ-9 Adherence and Distal Outcomes  
Correlations were explored among baseline PHQ-9 scores, Month 5 PHQ-9 scores, and 
average monthly PHQ-9 adherence across five months. Average monthly PHQ-9 were highly 
correlated (see Table 16). The correlations among baseline PHQ-9 scores and Months 2-5 PHQ-9 
adherence trended toward (Months 2 and  5) or were correlated (Months 3 and 4). The correlation 
between Month 5 PHQ-9 scores and Month 0 PHQ-9 Adherence trended toward significance.  
Step 1: Linear and Quadratic Latent Growth Curve Modeling 
 The data were first subjected to a basic linear growth curve model (LGCM) to evaluate a 
linear trajectory of change over the five-month active implementation period.  
Table 16. Correlations among continuous variables of interest. 
 BL PHQ9 M5 PHQ9 M0  M1  M2  M3  M4  M5  
BL PHQ9 1.00 0.14† 0.02 -0.03 -0.18† -0.26* -0.28* -0.18† 
M5 PHQ9 - 1.00 0.19† 0.03 0.07 0.11 -0.09 0.17 
M0 - - 1.00 0.73** 0.46** 0.40** 0.20† 
 
0.23* 
M1  - - - 1.00 0.56** 0.49** 0.45** 0.45** 
M2  - - - - 1.00 0.63** 0.47** 0.40** 
M3  - - - - - 1.00 0.73** 0.61** 
M4  - - - - - - 1.00 0.79** 
M5  - - - - - - - 1.00 
Note. † p > 0.05 but < 0.10; *p<0.05; **p<0.001. 
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Figure 2. Basic LGCM model. t0 to t5 indicate observed average monthly clinician adherence 
scores, i and s represent latent intercept and slope variables to be estimated. 
 
Unstandardized average estimates for the intercept (I = 0.37, p < 0.0001) and slope (S = 
0.06, p < 0.001) suggested that the mean trajectory of adherence scores demonstrated an increase 
over time. Slope and intercept variances were also statistically significant (0.27, p < 0.0001 and 
0.02, p < 0.0001, respectively), implying that some clinicians had higher or lower intercept 
adherence values than others, and that clinicians demonstrated significant variability in their rate 
of adherence change over time. Finally, there was a negative covariance between the slope and 
intercept (-0.033, p < 0.008), implying that clinicians who started out with higher adherence scores 
were more likely to experience score decline over the five-month period. Model fit indices 
suggested a poor fit to the data given the RMSEA value greater than the recommended cutoff of 
0.06 and Chi-squared test with p < 0.01 (BIC = 755.58; χ2(df) = 33.84(16), p < 0.01; RMSEA(90%) 
= 0.110 (CI: 0.06, 0.16). Overall, these results suggest substantial individual variation in intercept 
and slope of change in adherence scores, indicating that GMM analysis would be appropriate to 
identify patterns in individual trajectories of change. 
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 The adherence score data was then subjected to a LGCM model including a quadratic term 
in order to evaluate the potential for a non-linear trajectory of change in average adherence scores 
across months. Model fit indices for the quadratic model (BIC = 762.44; χ2(df) = 24.62(12), p < 
0.05; RMSEA(90%) = 0.11 (CI: 0.04, 0.17) indicate less optimal fit than the linear LCGM indices 
(higher BIC value, χ2diff (4) = 8.83 exceeding 9.49 based on p < 0.05). As a result, the linear 
trajectory of change was deemed best fit for the adherence data. 
Step 2: Clustered Latent Class Growth Analysis (LCGA) 
 The data were then subjected to a clustered latent class growth analysis (LCGA) to assess 
the presence of unique trajectories of change in PHQ-9 adherence over time while accounting for 
variation due to clinicians nested within sites.  
Figure 3. LCGA/GMM Model. t0 to t5 indicate observed average monthly clinician adherence 
scores, i and s represent latent intercept and slope variables to be estimated, c represents the latent 
class membership variable. 
 
The LCGA approach was selected as an exploratory first step prior to engaging in GMM 
per the recommendations Jung and Wickrama (2008). LCGA models were fit with k = 1 to k = 5  
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classes (see Table 17 for fit statistics by number of classes).  No convergence issues were 
identified.  
LCGA model fit statistics. The LCGA models were compared on model fit statistics (see 
Table 17). Although the k = 4 and k = 5 models had the lowest BIC values, both models had classes 
with very small membership (i.e. classes with 4, 8, or 9 clinicians), suggesting that the classes may 
not be “true” or reliable classes given the small overall sample size. As a result, the k = 4 and k = 
5 class models were not deemed to be the optimal fit for the data. The k = 2 model had the highest 
entropy value across all models as well as class membership representing substantial proportions 
of the data. However, the k = 3 model had a smaller BIC than the k = 2, suggesting the k = 3 model 
was a better fit model overall. In sum, the k = 2 or k = 3 models appear to be the best fit for 
consideration. The average latent class probabilities (Table 18 and 19) for both the k = 2 and k = 3 
models enable the assessment of the adequacy of classification. Successful classification of 
clinicians into classes would result in high probabilities. Per recommendations from Geiser (2012), 
probabilities higher than 0.80 are considered adequate. Both the k = 2 and k = 3 models have 
adequate classification, as both have class probabilities greater than 0.90. 
Table 17. LCGA model fit results. 
Fit Statistics 1 Class 2 Classes 3 Classes 4 Classes 5 Classes 
LCGA      
LL 
(parameters) 
-456.94 (8) -378.27 (11) -349.68 (14) -333.52 (17) -313.31 (20) 
BIC 950.05 806.28 762.66 743.90 717.06 
SSABIC 924.80 771.56 718.47 690.24 653.93 
Entropy  0.929 0.878 0.898 0.880 
Group Size (%)      
C1 92 (100.00%) 73 (79.35%)  48 (52.17%) 46 (50.00%) 47 (51.09%) 
C2  19 (20.65%)  13 (14.13%)  9 (9.78%)  8 (8.70%) 
C3   31 (33.70%)  33 (35.87%) 24 (26.09%) 
C4    4 (4.35%) 4 (4.35%) 
C5     9 (9.78%) 
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Figure 4. BIC and Entropy comparisons for unconditional LCGA models with different numbers 
of classes. 
 
 
Table 18. LCGA k = 2 Average Latent Class Probabilities for Most Likely Latent Class 
Membership (Row) by Latent Class (Column) 
  Class 1 Class 2 
Class 1 0.962 0.038 
Class 2 0.011 0.989 
 
Table 19. LCGA k = 3 Average Latent Class Probabilities for Most Likely 
Latent Class Membership (Row) by Latent Class (Column) 
 
  Class 1 Class 2 Class 3 
Class 1 0.942 0.001 0.038 
Class 2 0.011 0.922 0.057 
Class 3  0.058 0.002 0.940 
 
LGCA class trajectories. Initial exploration of the k = 2 model trajectories (see Figure 5) 
indicate two groups with similar slopes of change. Class 1 (N = 19) represents a minority of 
clinicians who appear to have completed the PHQ-9 (averaging a score of “1” on adherence) at 
Month 0 and then continued consistent use over time (the “High and Maintaining” Class). The 
change in Class 1’s adherence over time suggests that clinicians in Class 1 occasionally 
administered the PHQ-9 but did not often review scores or discuss with their clients. Class 2, with 
the largest number of clinicians (N = 73), began with fairly low adherence scores at Month 0 
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(immediately post training), and then demonstrated a slight increase in adherence over time (the 
“Low with Improvement” Class). However, average adherence values below one suggest that 
clinicians in Class 2 are reporting infrequent administration of the PHQ-9.  
 The k = 3 model trajectories indicate that the majority of clinicians were assigned to Class 
1 and exhibited low PHQ-9 adherence at Month 0 and stayed low over time (the “Low and 
Maintaining” Class, N=48). In contrast, approximately 15% of clinicians were assigned to Class 
2, a class that began with high PHQ-9 adherence and demonstrated an increase in adherence over 
time (the “High with Improvement” Class, N = 13). Finally, Class 3 represented approximately 
35% of clinicians who started low in their adherence to MBC and experienced an increase in 
adherence over the five months following training (the “Low with Improvement” Class, N = 31).  
Table 20. Intercept and linear slope estimates for k = 2 and k = 3 LCGA models. 
 Intercept 
(M) 
Standard 
Error 
p value Slope (M) Standard 
Error 
p value 
k=2 
Class 1 
 
1.094 
 
0.231 
 
0.000*** 
 
0.099 
 
0.079 
 
0.212 
Class 2 0.152 0.057 0.008** 0.064 0.021 0.002** 
k=3 
Class 1 
 
0.220 
 
0.095 
 
0.020* 
 
-0.021 
 
0.031 
 
0.500 
Class 2 1.031 0.301 0.001** 0.202 0.077 0.009** 
Class 3 0.380 0.198 0.054† 0.123 0.049 0.012* 
Note. † p > 0.05 but < 0.10; *p < 0.05; **p<0.01; ***p<0.001 
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Figure 5. LGCA k = 2  and k = 3 model class trajectories. 
LCGA summary. In summary, the exploratory LCGA models suggested that either a k =
2 (higher entropy) class or k = 3 class (lower BIC) model fit the data. Given that the k = 3 model 
provides the lowest BIC value, has class membership above 10% for all classes, and enables the 
identification of a unique class of clinicians who demonstrate decline in PHQ-9 adherence over 
time), the k = 3 model was deemed the optimal fit for further evaluation. The k = 3 model identified 
three separate classes of clinicians: a) Class 1 - “Low and Maintaining”; b) Class 2 – “High with 
Improvement”; and c) Class 3 – “Low with Improvement”. Further evaluation of the model is 
needed using GMM, as LCGA tends to overestimate the number of classes as it fails to model 
heterogeneity of individuals within classes (Wickrama et al., 2016).  
Step 3: Clustered Three-Step Growth Mixture Modeling (GMM) 
GMM models were then run assuming that all classes had equal variances and covariances 
(i.e. GMM-with class invariant variances and covariances/GMM-CI). Convergence issues were 
identified for the k = 5 GMM-CI model, suggesting over-extraction of classes. 
GMM-CI model fit statistics. The k = 5 solution was discarded as it failed to replicate the 
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maximum loglikelihood value. Although the k = 4 and k = 3 models had a slightly lower BIC 
values than the k = 2 model, both models had a class with only five percent to 10% of clinicians 
(see Table 21). This small class membership suggests that the classes may not be “true” classes, 
therefore providing evidence supporting the k = 2 model. The k = 2 model also had adequate 
average class probabilities, suggesting acceptable class classification. The k = 2 model was 
selected for further exploration. Compared to the LCGA models, all GMM-CI models 
demonstrated lower BIC values therefore suggesting that the GMM models are a better fit for the 
data. 
Table 21. GMM-CI model fit statistics. 
Fit Statistics 1 Class 2 Classes 3 Classes 4 Classes 5 Classes* 
GMM - CI      
LL (parameters) -351.91 (11) -337.13 (14) -318.82 (17) -302.03 (20) -297.52 (23) 
BIC 753.56 737.57 714.50 694.50 699.03 
SSABIC 718.84 693.37 660.84 631.37 626.43 
Entropy  0.887 0.889 0.896 0.889 
Group Size (%)      
C1 92 (100.00%) 17 (18.48%) 68 (73.91%) 62 (67.39%) 58 (63.04%) 
C2  75 (81.52%) 17 (18.48%) 13 (14.13%) 12 (13.04%) 
C3   7 (7.61%) 7 (7.61%) 7 (7.61%) 
C4    10 (10.87%) 11 (11.96%) 
C5     4 (4.35%) 
Note. * = the model failed to replicate the maximum loglikelihood value with maximum number 
of starts, therefore estimates are untrustworthy and suggest over-extraction of classes. 
 
Clustered GMM with class variant variances and covariances (GMM-CV). GMM-CV 
models were then run assuming all classes had unequal variances and covariances (i.e. GMM-with 
class variant variances and covariances/GMM-CV). GMM models were explored for k = 1 to k = 
5 classes to enable comparison to the LCGA and GMM-CI results. Convergence issues were 
identified for the k = 3, k = 4, and k = 5 GMM-CV models, suggesting over-parameterization and 
over-extraction of classes. 
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GMM-CV model fit statistics and comparison to GMM-CI. The k = 3, k = 4, and k = 5 
models were determined to be of poor fit for the data given low class membership in class two (k 
= 3 model) and convergence issues in the k = 4 and k = 5 models. The k = 2 GMM-CV with class 
variant variances and covariances was then compared to the k = 2 GMM-CI model with class 
invariant variances and covariances. The k = 2 GMM-CI model BIC (737.57) was lower than the 
k = 2 GMM-CV model BIC (753.88), suggesting an overall better fit for the GMM-CI k = 2 model. 
Per recommendations from Geiser (2012), classification probabilities higher than 0.80 are 
considered adequate. The k = 2 GMM-CI model also had adequate classification, as both classes 
had class membership probabilities greater than 0.90 (see Table 23). The GMM-CI model was 
selected as the final model for further exploration. 
Table 22. GMM-CV model fit statistics. 
Fit Statistics 2 Classes 3 Classes* 4 Classes** 5 Classes** 
GMM - CV     
LL (parameters) -338.51 (17) -311.22 (23) -304.98 (29) -309.34 (35) 
BIC 753.88 726.45 741.09 776.95 
SSABIC 700.22 653.85 649.55 666.47 
Entropy 0.930 0.835 0.821 0.896 
Group Size (%)     
C1 11 (11.96%) 50 (54.35%)  0 (0.00%) 31 (33.70%) 
C2 81 (88.04%) 9 (9.78%)  39 (42.39%) 54 (58.70%) 
C3  33 (35.87%) 9 (9.78%) 0 (0.00%) 
C4   44 (47.83%) 7 (7.61%) 
C5    0 (0.00%) 
Note. * = the model resulted in small class membership, suggesting the class may not be a true 
class; ** = the model failed to replicate the maximum loglikelihood value with maximum number 
of starts, therefore estimates are untrustworthy and suggest over-extraction of classes. 
 
Table 23. GMM-CI k = 2 Average Latent Class Probabilities for Most Likely Latent Class 
Membership (Row) by Latent Class (Column) 
 Class 1 Class 2 
Class 1 0.939 0.061 
Class 2 0.019 0.981 
 
 69
GMM-CI class trajectories The final selected k = 2 GMM-CI model identified two classes 
with unique intercept and slope values. Class 1 was identified as a “High and Maintaining” class, 
while Class 2 was identified as a “Low and Improving” class. These trajectories represent a 
departure from the LGCA results, as Class 1 clinicians no longer demonstrate an increase in PHQ-
9 adherence over time, but instead largely maintain their level of adherence over time (slope p = 
0.973). Class 2 demonstrated change over time (p < 0.01), with MBC adherence increasing across 
the five-month period.  
Table 24. Intercept and linear slope estimates for the k = 2 GMM-CI. 
 Intercept 
(M) 
Standard 
Error 
p Slope (M) Standard 
Error 
p 
Class 1 1.309 0.200 0.000*** -0.002 0.070 0.973 
Class 2 0.124 0.056 0.027* 0.081 0.028 0.003** 
Note. . trend toward significance; *p < 0.05; **p < 0.01; ***p < 0.001. 
 
Figure 6. GMM-CI k = 2 model class trajectories. 
Step 4: Predictors and Distal Outcome Differences Across GMM-CI Classes 
GMM-CI Predictors. Age, race, gender, theoretical orientation, and years experience did 
not emerge as predictors of class membership in the GMM-CI k = 2 model (see Table 25).   
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Table 25. Multiple logistic regression predictors of GMM-CI class membership for k = 2 model. 
Predictor Class Contrast Coefficient SE t statistic p 
Age 1 v. 2 -0.02 0.03 -0.81 0.42 
Race 1 v. 2 2.50 4.38 0.57 0.57 
Gender 1 v. 2 0.50 1.30 0.38 0.70 
Theoretical Orientation 1 v. 2 0.38 0.29 1.32 0.19 
Years Experience 1 v. 2 0.25 0.51 0.48 0.63 
Note. Class 1 = High and Maintaining; Class 2 = Low and Improving. 
 GMM-CI Distal Outcome. There were no differences between classes with respect to 
mean baseline or Month 5 average PHQ-9 scores using Wald’s Chi-squared tests for either all new 
and ongoing depression pathway clients (see Table 26) or for new clients only (see Table 27). 
Table 26. Chi squared tests for mean differences in baseline and Month 5 PHQ-9 scores between 
classes in k=2 GMM-CI model. 
Distal Outcome 
Class 1 High and 
Maintaining 
M (SD) 
Class 2 Low and 
Improving 
M(SD) Χ2 p 
Baseline PHQ-9 13.93 (4.33) 12.60 (3.09) 1.73 0.19 
Month 5 PHQ-9 10.95 (6.96) 12.72 (6.04) 0.62 0.43 
 
Table 27. Chi squared tests for mean differences in baseline and Month 5 PHQ-9 scores between 
classes in k=2 GMM-CI model for new clients only. 
Distal Outcome 
Class 1 High and 
Maintaining 
M (SD) 
Class 2 Low and 
Improving 
M(SD) Χ2 p 
Baseline PHQ-9 15.10 (7.61) 15.20 (9.47) 0.002 0.96 
Month 5 PHQ-9 13.012 (5.03) 11.86 (8.25) 0.382 0.54 
 
Study 2 Discussion 
This study was the first to our knowledge to apply GMM, a person-centered analytic 
approach, to quantitatively characterize patterns of clinician MBC use. Contrary to initial 
hypotheses anticipating three unique groups of clinicians, the two class GMM-CI model with class 
invariant variances and covariances was selected as the best fit model for the data (H1). This model 
identified two classes of clinicians with unique patterns of MBC adherence over time; one class 
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that started with high adherence scores and maintained them (Class 1 - High and Maintaining) and 
one that started with low adherence scores and increased them (Class 2 - Low and Improving) over 
the five month active implementation period. Despite only supporting two unique groups, study 
results did support the presence of a class of clinicians starting with low adherence and slowly 
increasing over time. This finding partially supported study hypothesis two (H2), which predicted 
that clinicians would demonstrate an increase in adherence over the five month active 
implementation period in line with Roger’s diffusion of innovations theory (Rogers, 2010). 
However, overall adherence was significantly lower than hypothesized, as average MBC 
adherence scores over time were often below or close to “1” (i.e. PHQ-9 administration only) 
across both classes of clinicians. Finally, study findings failed to support study hypothesis three 
(H3), as there were no differences between the two classes with respect to age, gender, race, 
theoretical orientation, or years of experience in mental health treatment. There were also no 
differences between classes with respect to depression symptom outcomes at Month 5 post 
training. 
Although the findings did not support several of the hypotheses identified prior to analysis, 
the two class GMM-CI model did offer important insight into clinicians’ approaches to integrating 
MBC into their clinical practice. The majority of clinicians (i.e. the “Low and Improving” class) 
appeared to be slow to begin use of MBC with adherence, but experienced a increase in adherence 
over time. This trend is perhaps not surprising, as clinicians should improve their use of MBC after 
receiving workshop training followed by ongoing consultation and supervision throughout the 
five-month active implementation period. Previous studies have highlighted the limitations of 
workshop training for promoting behavior change, therefore it is common practice to incorporate 
ongoing consultation into training approaches to encourage active learning and application of 
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novel practices like MBC (Beidas & Kendall, 2010). Ongoing support provided in the parent study, 
either via consultation sessions focused on clinical questions or implementation teams focus on 
contextual and practical challenges, may have enabled clinicians in Class 2 to gain the skills needed 
and overcome barriers to enhance their adherence to MBC.  
An alternative explanation for the “Low and Improving” class’s improvement over time 
may be improvement in their self-efficacy and control over using the PHQ-9 in session. As noted 
above, time and resource limitations are some of the most commonly identified barriers to using 
EBPs like MBC in community mental health settings (Baker et al., 2010; Jensen-Doss & Hawley, 
2010; Lewis & Simons, 2011; Stewart et al., 2012). Clinicians often express beliefs that these 
barriers are outside their control and prevent their use of MBC because MBC requires additional 
time and they must comply with organizational policies that require large caseloads and high 
productivity requirements (Scott & Lewis, in prep).  However, recent studies have suggested that 
clinicians may be able to overcome these challenges by achieving self-efficacy with EBPs like 
MBC (Shapiro et al., 2012), as MBC can actually streamline their work in session to focus on key 
problems. This increase in self-efficacy and efficiency using the PHQ-9 may then promote 
increased use of MBC over time (Scott, Wahlen, Lyon, & Lewis, in prep). Given that all clinicians 
had at least some MBC use immediately following training, it is possible that clinicians in the 
“Low and Improving” class experienced increases in MBC adherence over time due to enhanced 
feelings of self-efficacy upon successful application. Additional research is needed to evaluate the 
degree to which changes in MBC adherence over time may be due directly to enhanced clinician 
self-efficacy in MBC use, ongoing consultation and supervision, or a combination of both factors. 
In contrast to the “Low and Improving” class, the “High and Maintaining” class captured 
a minority of clinicians who started off with higher adherence to MBC (i.e. scores indicating 
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frequent administration of the PHQ-9) and maintained this adherence over the five month active 
implementation period. These clinicians may be early adopters of MBC, or individuals who have 
high interest in learning to use MBC and begin using it immediately after receiving training 
(McHugh & Barlow, 2010). Future research efforts might explore clinicians’ use of MBC prior to 
training as a predictor of post-training use in order to discern between post-training early adopter 
clinicians and those who had been employing MBC prior to training. This approach may provide 
additional insights into patterns of clinician MBC use not identified in the present study. 
It is surprising that some clinicians failed to improve their use of MBC over time despite 
ongoing support through consultation or implementation team meetings. Clinicians in the “High 
and Maintaining” class had average adherence scores between “1” and “1.5,” suggesting they 
infrequently reviewed or discussed scores with clients across the five months post training. One 
possible explanation for both the “High and Maintaining” class’s failure to improve their use of 
MBC as well as both classes’ limited overall adherence to MBC (i.e. many adherence scores of 
“0”, maximum around “1.5”) is clinician’s tendency toward selective use of MBC with only some 
of their clients. Despite receiving training focused on use of the PHQ-9 with all depressed clients 
regardless of client complexity (e.g. client diagnostic comorbidities, role functioning, crisis 
management), clinicians still reported selectivity in deciding with whom they would use the PHQ-
9. As noted in Study 1 above, clinicians were hesitant to use the PHQ-9 with full adherence when 
clients were not engaged in treatment or when they had complex diagnoses.  
These findings regarding clinician selective use of EBPs like MBC have also been reported 
in the research literature. Studies have identified high client comorbidity and client environmental 
chaos (Mitchell, 2011; Schoenwald, Halliday-Boykins, & Henggeler, 2003) as predictors of 
clinicians’ limited use of EBPs. These findings may explain why average adherence to MBC was 
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so low across both classes of clinicians in the present study (i.e. approximately 30%  of scores 
reflected “0” adherence across all months), especially if the majority of clients seen by 
participating clinicians were quite complex. Future research is needed to identify client and 
clinician factors in this sample that limited MBC use and to explore methods beyond the training 
and consultation provided in the parent R01 study that may encourage clinicians to use MBC with 
even the most complex clients.  
It is also important to note that the present study did not identify clinician characteristics 
that predicted class membership. These findings failed to replicate previous literature suggesting 
that gender, age, theoretical orientation, and years of experience may predict openness to and use 
of EBPs (Aarons, 2004; Beidas et al., 2015; Nelson & Steele, 2007; Stewart et al., 2012). It remains 
unclear what factors may contribute to whether clinicians fall into the “High and Maintaining” 
class or the “Low and Increasing” class. This study specifically explored individual clinician 
factors, such as years experience, race, and gender, which may not be the most influential variables 
in determining clinicians’ patterns of MBC practice. However, more research is needed to explore 
additional organizational and individual-level predictors of class membership that may serve as 
barriers to EBP use such as attitudes toward MBC, clinician self-efficacy, and site organizational 
culture (Aarons, 2004; Aarons & Sawitzky, 2006; Jensen-Doss & Hawley, 2010).  
Finally, class membership did not predict differences in clinical outcomes, a finding that is 
surprising given the strong evidence for MBC’s effectiveness in enhancing depression outcomes 
(Lambert et al., 2001). However, the studies establishing MBC as effective provided clinicians 
with researcher-generated reports showing their clinicians progress, perhaps facilitating clinician 
review of client symptom scores. In the present study, clinicians had to manually enter PHQ-9 
scores into the EHR and choose to review the trajectory, two additional steps that perhaps limited 
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their review and discussion of scores. Additionally, although there is limited evidence regarding 
the necessary dose of MBC needed to promote change, Bickman and colleagues (2016) did note a 
dose-response relationship in their work using MBC with youth, with higher MBC adherence 
resulting in faster improvement. Other studies have also highlighted the importance of clinician 
and client discussion of feedback in order to maximize MBC’s impact on symptom change 
(Lambert et al., 2001). It may therefore be the case that both classes of clinicians failed to apply 
the needed dose of MBC to promote change. More exploration of this potential dose-reponse 
relationship is warranted in order to identify the necessary dosage of MBC required to maximize 
symptom improvement.  
Limitations 
 Several limitations should be noted regarding the study findings. First, outcomes from this 
GMM analysis study represent adherence patterns for MBC for depression across 10 sites within 
a specific community mental health organization. Recruitment for the parent R01 study is ongoing, 
therefore it is unclear how the results might change with the integration of the additional two sites 
(total of 12). It is also unclear the degree to which these findings might generalize to other 
diagnoses beyond depression or to other community mental health clinics and clinicians. Second, 
many clinicians opted not to use MBC with many of their clients, resulting in substantial 
frequencies of “0” scores for adherence as well as significant missing data and a small clinician 
sample size. This small sample size may have limited the ability to retain additional classes of 
clinicians who may have had unique trajectories of change in MBC adherence. Third, the need to 
have clinician-level indicators of adherence and depression symptom outcomes over time resulted 
in the computation of average monthly adherence and average baseline and Month 5 PHQ-9 scores 
for each clinician. Averaging the data in this way results in an inability to evaluate the variability 
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of clinician MBC adherence and PHQ-9 scores within each time point, thereby reducing the 
number of observations as well as the potential to detect unique patterns of clinician adherence 
with individual clients. Additionally, average PHQ-9 score computations incorporated both new 
(i.e. clients just beginning therapy) and ongoing clients who may have been in various stages of 
symptom improvement at Month 5. As a result, the lack of findings regarding depression symptom 
outcomes may not be reliable due to significant variation in clients’ amount of received therapy 
(i.e. ranging from a few sessions to months of treatment). Finally, there was substantial missing 
data for average clinician baseline and Month 5 PHQ-9 scores. Although these scores were 
imputed to enable comparisons across classes, estimates and group comparisons may not be 
trustworthy given the small sample of complete observations. 
Conclusions 
The findings from this study are the first attempt, to our knowledge, to identify unique 
patterns of change in clinicians’ MBC adherence over time following workshop training. Results 
of the GMM analysis suggested that clinicians had two patterns of MBC adherence over time, high 
use that maintained and low use that increased. However, clinicians used MBC with full adherence 
quite infrequently, suggesting that clinicians failed to implement MBC with their depressed clients 
despite ongoing support from consultation and implementation teams during the active 
implementation period. These results may have important implications for identifying how much 
MBC is needed to promote depression symptom change, identifying clinicians who may benefit 
from targeted strategies to enhance adherence (e.g. additional training, supervision, evaluation of 
barriers), and ultimately for identifying MBC’s core components and dosage of those components 
required to enhance depression outcomes for clients most in need. 
Chapter 3: Study 3 Introduction 
 77 
Although there is strong evidence supporting MBC’s effectiveness, few studies have 
explored the putative mechanisms of change associated with MBC’s impact on depression 
symptoms. The strongest evidence for how MBC works to produce symptom change currently 
comes from the psychopharmacology literature where MBC is typically used to inform decisions 
about antidepressant dosage and switching medications. Large randomized controlled trials such 
as the Sequenced Treatment Alternatives to Relieve Depression trial (STAR*D; Trivedi et al., 
2006), Combining Medications to Enhance Depression Outcomes (CO-MED; Rush et al., 2011) 
and the Clinical Outcomes in Measurement Based Treatment trial (COMET; Yeung et al., 2012) 
suggest that MBC works by enabling the clinician to regularly evaluate symptom progress, make 
appropriate adjustments to medication dosages per recommended guidelines or an automated 
clinical decision support system, and ultimately see improved symptom outcomes (Morris & 
Trivedi, 2011; Trivedi et al., 2007). Additionally, use of MBC may enhance client adherence to 
medication regimens, perhaps as a result of frequent physician monitoring of dosages and side 
effects (Warden et al., 2014). MBC may also enable better collaborative stepped care among health 
providers, thereby enhancing the quality of both medication treatment and additional adjunctive 
care (Unützer & Park, 2012). In summary, MBC in psychopharmacology appears to operate by 
enabling clinicians to select the optimal dosages and dosage changes of psychiatric medication 
across treatment, thereby leading to improvements in outcomes for clients. 
MBC’s Putative Mechanisms of Action 
Unfortunately, psychotherapy approaches to depression treatment often lack the specific 
guidelines present in pharmacology for when and how much to adjust the “dosage” of treatment. 
The variability in community clinician approaches to providing usual care psychotherapy makes 
identification of potential mechanisms of change quite difficult. However, correlational and 
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qualitative studies of MBC applied in psychotherapy suggest several potential ways MBC may 
work to enhance outcomes in psychotherapy. 
Symptom understanding. One putative mechanism of action of MBC in psychotherapy 
may be enhanced client symptom understanding resulting from completion of objective symptom 
measures prior to each clinical session. For example, Dowrick and colleagues (2009) found that 
clients who completed depressive symptom self-reports expressed that the measures allowed them 
to quantify and gain a better understanding of their depression symptoms. Additionally, Hall and 
colleagues (2014) reported that families felt the process of filling out the symptom measures was 
helpful for reflecting on progress and for being better prepared for each clinical session. MBC may 
also assist clients in their ability to better communicate their symptoms and experience in therapy 
to their clinician (Hall et al., 2014; Unsworth, Cowie, & Green, 2012; Wolpert, Curtis-Tyler, & 
Edbrooke-Childs, 2016).  
Assessment accuracy. MBC may also produce change by enhancing clinician accuracy in 
their evaluation of client treatment progress and outcomes. It may also enhance clinicians’ ability 
to quickly select interventions that are best suited to the client’s symptoms. Strong evidence in the 
research literature suggests that clinicians have limited success gauging outcomes and predicting 
improvement by relying on clinical judgment alone (Grove, Zald, Lebow, Snitz, & Nelson, 2000; 
Jacinto, Lewis, Braga, & Scott, 2016). Instead, it is typically advisable for clinicians to rely on a 
combination of clinical experience and objective evaluation, such as by use of MBC and other 
reliable and valid assessments of progress (Jacinto et al., 2016; Sapyta, Riemer, & Bickman, 2005). 
MBC may function to enhance clinicians’ objective evaluation of client progress, which may 
ultimately allow them to provide more effective therapy and enhance outcomes (Kelley & 
Bickman, 2009). It may also allow clinicians to more systematically identify risk, therefore 
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enabling intervention prior to treatment failure or clinical deterioration (Lambert et al., 2005; 
Unsworth et al., 2012).  
Intervention selection and tailoring. Additionally, clinicians may be able to more rapidly 
select interventions in between clinical sessions that would be an optimal fit for client symptoms, 
thereby enhancing the rate of change (Unsworth et al., 2012; Wolpert et al., 2016). They may also 
use MBC to “triage” clients based on their need for different dosages of therapy. For example, 
clinicians may use MBC to determine client severity, select an appropriate number of therapy 
sessions, and ultimately provide more tailored and effective treatment (Unsworth et al., 2012). 
Additionally, MBC may serve to identify the best clinician with the proper training to address 
client needs (Martin, Fishman, Baxter, & Ford, 2011). Clinicians may also use MBC to inform the 
specific questions asked in their own clinical supervision, thereby asking targeted questions and 
gaining better oversight of their most challenging clients (Lambert & Hawkins, 2001; Unsworth 
et al., 2012). 
Treatment engagement. MBC may also operate by enhancing client treatment 
engagement. Treatment engagement has been defined in numerous ways in the psychotherapy 
literature, but is typically viewed as a client’s emotional investment in treatment and willingness 
to make recommended behavioral changes (Lindsey et al., 2014). Treatment engagement is a 
multifaceted domain that has been measured by evaluating client treatment attendance/retention, 
participation in therapy sessions, and the clinician and client therapeutic alliance (Lindsey et al., 
2014). Eisen and colleagues (2000) reported that the process of providing feedback (i.e. accessing 
treatment progress scores in session with the client) led to higher client reports of actively making 
decisions about treatment and feeling more engaged in the process of treatment when compared to 
clients who did not receive feedback in a quasi-experimental intervention trial. Other studies, 
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specifically in substance abuse treatment, suggested that this enhanced perception of therapy 
involvement and improved communication with care providers resulted in higher treatment 
retention as well as enhanced clinical outcomes (Simpson, Joe, Rowan-Szal, & Greener, 1997, 
1995). A recent meta-analysis specifically identified assessments, including MBC, as the most 
commonly employed approaches for encouraging client treatment engagement (Lindsey et al., 
2014). These findings imply that enhanced treatment engagement may be an important mediator 
of the relation between MBC use and client outcomes and perhaps serve as a mechanism of change.  
Treatment attendance has often been employed as a measure of client engagement as it 
may serve as an indicator of therapy “dosage” (Simpson et al., 1997, 1995). Poor treatment 
attendance is common in community mental health settings, with estimates suggesting that as 
many as 25% of community clients drop out of treatment prior to their first therapy session and as 
many as 35% drop out after the first therapy session (Simon et al., 2012). Even outside of 
community mental health, client rates of attrition from therapy range from 20% to 50% (Hatchett 
& Park, 2003; Swift & Greenberg, 2012). This poor attendance has been linked to reduced 
symptom improvement for clients (Cahill et al., 2003; Simpson et al., 1995), as well as reductions 
in morale and job satisfaction for clinicians providing treatment (Mensinger, Diamond, Kaminer, 
& Wintersteen, 2006).  
An additional element of client treatment engagement is client willingness to engage in 
therapy skill practice both in and between sessions (i.e. therapy participation; Lindsey et al., 2014). 
Though not formally tested as a mechanism of change of MBC, enhanced client practice of therapy 
skills outside session upon seeing MBC progress may also explain MBC’s effectiveness (Anker, 
Duncan, & Sparks, 2009). There are numerous elements that have been associated with client 
participation, including client commitment to therapy, willingness to spend time on therapy skills, 
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and desire and perception of therapy’s importance (Karver, Handelsman, Fields, & Bickman, 
2005; Littell, Alexander, & Reynolds, 2001). However, few of these elements have been explicitly 
defined in the literature (Littell et al., 2001), and additional research is warranted to understand the 
variation in client participation and its potential impact on depression outcomes. 
Finally, research in the couples intervention literature suggests that MBC may result in 
greater therapy engagement via an improved therapeutic alliance between clinician and client, 
thereby leading to enhanced treatment outcomes (Anker et al., 2009; Unsworth et al., 2012). 
Clients may also experience enhanced expectancies about their potential for change by seeing their 
current progress, which may simultaneously enhance the alliance and client improvement (Anker 
et al., 2009; Hall et al., 2014; Unsworth et al., 2012).  
Moderated Mediation Techniques to Evaluate MBC’s Mechanism of Action 
 Given the pragmatic nature of the parent R01 study and the challenges associated with 
treatment retention in community mental health settings, treatment engagement was identified as 
a putative MBC mechanism of change for further evaluation. Moderated mediation analysis is a 
novel approach to testing mediation effects that deviates from more traditional approaches as 
described by Baron and Kenny (1986). Baron and Kenny previously identified four key 
requirements for mediation analysis: a) variation in the independent variable must be associated 
with variation in the dependent variable; b) variation in the independent variable must be 
associated with variation in the proposed mediator; c) variation in the mediator must be associated 
with variation in the dependent variable; and d) when the independent and dependent variables are 
controlled for (with the mediator included), the relation between them is attenuated (Baron & 
Kenny, 1986). However, more recent work by Bollen (1989), Hayes (2013), and Preacher (2015) 
suggested that a lack of correlation between the independent and dependent variables (i.e. the direct 
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effect) does not necessarily imply lack of causation, therefore mediation analysis can be conducted 
even in the absence of a direct effect.  
 Additionally, more modern approaches to mediation have explored mediation and 
moderation simultaneously. While unusual, this novel approach allows for the estimation of not 
only a mediating effect, but also the potential for the independent variable to moderate the relation 
between the mediator and the dependent variable (Hayes, 2013). In the case of treatment 
engagement as a mediator, MBC adherence could be explored as a potential moderator of the 
relation between engagement and depression symptom outcomes. If adherence does in fact 
moderate the relation, results would suggest that more adherence creates better quality sessions, 
thereby enhancing both client engagement in treatment and outcomes. This concept is supported 
in the EBP adherence literature, as good adherence is often a presumed prerequisite for delivery 
of EBPs with fidelity (Perepletchikova & Kazdin, 2005; Sharpless & Barber, 2009). In sum, this 
approach provides a novel way to evaluate whether client engagement serves as MBC’s 
mechanism of action, as well as to assess the degree to which a higher MBC adherence may be 
vital for maximizing MBC’s effectiveness.  
The Present Study 
In sum, a gap exists in the literature regarding the process and mechanisms by which MBC 
acts to produce change in depression symptom outcomes. Although it appears that providing 
feedback to both therapists and clients about client treatment progress is optimal (Lambert et al., 
2005), more research is needed to explore how this feedback process operates to create change in 
depression symptoms. Prior evaluations of putative mechanisms of change for MBC have 
employed correlational approaches (Eisen et al., 2000), thereby limiting the ability to identify a 
causal relation between mechanisms of interest and improved symptoms. The present study will 
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explore a formal simultaneous moderation and mediation analysis of one putative mechanism of 
change, treatment engagement measured by total client session attendance (Study 3 aim), in an 
effort to begin identifying MBC’s key mechanisms of action. 
Hypotheses 
It was anticipated that increased client engagement in treatment via increased session 
attendance would mediate the relation between early session clinician MBC adherence 
(independent variable) and client symptom outcomes (dependent variable) such that higher 
clinician MBC adherence results in greater client treatment engagement, leading to improved 
outcomes (H1). Additionally, clinician MBC adherence would moderate the relation between 
treatment attendance and client outcomes, suggesting that enhanced adherence leads to enhanced 
effectiveness of the additional therapy sessions attended (H2).  
Study 3 Methods 
Participants 
Participants included clients who were enrolled in the study and who were just beginning 
psychotherapy (i.e. new clients) at one of the 10 sites (N = 88). These participants were drawn 
from a larger sample of 196 enrolled clients recruited into the parent study as of January 2017. Of 
the 196, only 109 clients were identified as new clients, while the remaining 87 clients were 
receiving ongoing therapy. An additional 21 clients were excluded from the analysis as they did 
not provide any adherence or session attendance data, resulting in a total sample of 88 clients for 
analysis.  
Measures 
 Independent variable - adherence. Session one adherence scores and average session one 
and two adherence scores (independent variables for mediation modeling) were identified for each 
 84 
of the 88 enrolled clients included in the analysis. These adherence scores ranged from “0”, 
indicating no clinician MBC adherence, to “3”, indicating that the clinician administered, 
reviewed, and discussed the PHQ-9 with the client in the first session. An additional dichotomous 
adherence variable was also computed to identify clients who received at least some MBC at 
sessions one and/or two (i.e. a score of “1”, “2”, or “3”) or who received no MBC adherence (i.e. 
a score of “0”). These early session adherence scores were selected for the analysis as they were 
the earliest assessment of adherence prior to the client receiving the full “dose” of MBC across 12 
weeks of treatment. Given that a substantial number of clients do not attend beyond the first 
therapy session (Simon et al., 2012), exploring session one and session two adherence may present 
a unique opportunity to evaluate a causal relation whereby early MBC adherence impacts client 
treatment engagement and results in clients coming back for more sessions. This approach using 
early session data has been explored in other studies as a method for evaluating putative 
mechanisms of action, as it is assumed that interventions at early sessions will precede changes in 
mediator and outcome variables (Karno, 2007). 
 Mediator variable – total sessions attended. The putative mediator variable, client 
treatment engagement, was measured by computing the total number of sessions attended across 
12 weeks for all 88 clients included in the analysis. This 12-week period was selected as it is the 
standard acute phase of depression treatment in which clients are expected to achieve symptom 
change in clinical trials (March, Silva, & Vitiello, 2006). This 12-week period was also selected 
as the time frame for measuring symptoms given that many EBP approaches are brief in nature 
(e.g. 12 to 16 weeks).  
 Dependent variable – week 12 PHQ-9 scores. All 88 clients included in this analysis 
completed PHQ-9 measures as baseline and week 12 of treatment. Research specialists 
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administered these PHQ-9 measures to clients over the phone. Week 12 PHQ-9 scores served as 
the primary dependent variable/outcome measure for this analysis, and all analyses controlled for 
baseline PHQ-9 scores in order to adjust for variability in client initial depression severity.  
Covariates. The covariates selected for this analysis included client gender, race, and years 
of education. These three variables were selected as they have been explored as covariates in 
evaluating differences in depression symptom presentations and impact of interventions for 
depression. There are significant gender and racial differences in depression prevalence as well as 
symptom presentation (Barnes, Keyes, & Bates, 2013; Riolo, Nguyen, Greden, & King, 2005; 
Schuch, Roest, Nolen, Penninx, & de Jonge, 2014). Existing research has also demonstrated that 
higher years of client education are associated with fewer symptoms of depression (Ross & 
Mirowsky, 2006). Years of education also serves as one indicator of socioeconomic status, which 
has been established as a key indicator of risk for poor mental health (Braveman et al., 2005; 
Williams, Yu, Jackson, & Anderson, 1997).  Gender (male/female) and race (white/non-white) 
were included in the models as dichotomous variables, with a reference group of males for gender 
and white for race. Years of education was included in the models as a continuous variable. 
Data Nesting  
Given that clients were nested within clinicians and clinicians within sites, both clinician 
and site were explored as potential nesting variables to be accounted for in the analyses. Intra-class 
correlation values were computed to evaluate the impact of site on the variance in clinician 
adherence. Design effect scores were then calculated using the formula DEFF = 1 + (nc -1)ICC, 
where nc is the average cluster size (i.e. average number of clients per clinician Muthen & Satorra, 
1995). Per the recommendations of Muthen & Satorra (1995), design effects greater than two were 
used to determine the need to account for nesting in the mediation analysis. 
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Mediation Analysis 
All variables (independent, dependent, and mediator) were measured at the client level. 
Given this multi-level data, modeling procedures were employed in line with multilevel mediation 
recommendations from Lachowicz, Sterba, and Preacher (2015). The following relations were 
explored across three mediation models with unique independent variables: a) if there was an 
indirect effect of clinician MBC adherence (independent variable) via session attendance 
(mediator) on client outcomes (dependent variable); b) if there was a residual unmediated direct 
effect of clinician adherence on client depression symptom outcomes; and c) if clinician MBC 
adherence moderated the relation between session attendance and client symptom outcomes (see 
path diagrams in Figures 8, 9, and 10 below). Model one explored session one adherence alone as 
the independent variable, while model two explored average session one and session two 
adherence. Model three used a dichotomous adherence variable (i.e. if the client received any MBC 
adherence or not). All models were tested using multiple linear regression models (given 
continuous mediator and outcome variables) and were run in Mplus statistical software controlling 
for client baseline PHQ-9 scores, gender, race, and years of education. 
Power Analysis 
 A power analysis was conducted prior to engaging in mediation analysis in order to 
determine whether the sample of 88 clients had adequate power (at least 0.80) to detect direct and 
indirect effects. A Monte Carlo simulation study was conducted per recommendations from 
Muthén & Muthén (2002), which involved the generation of 10,000 data sets, each with 88 
clinicians clustered within sites of nine sizes (actual site sizes ranged from 1 to 26). All variables 
were simulated with means of zero and total variance of one. Mediation models were then run on 
these data sets, with all dependent variable residual variances fixed such that the total variance was 
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equal to one (Thoemmes, MacKinnon, & Reiser, 2010). Given that previous literature did not exist 
to guide the expected magnitude of the relation among variables, estimates were included in the 
simulation to represent small (R2 = 0.02), medium (R2 = 0.13), and large effects sizes (R2 = 0.26) 
for all paths (Cohen, 1988). All path estimates and residual variances were calculated using matrix 
algebra methods recommended by Thoemmes and colleagues (2010), Ma and Zeng (2014), and 
Fritz and MacKinnon (2007). The study sample of 88 was sufficient to detect direct and indirect 
path estimates with medium effect sizes. However, the study was not powered to detect small 
effect sizes, which may limit identification of significant, small but meaningful mediation. 
Table 28. Power analysis for mediation models. 
Path Estimate Power 
Small Effect Size   
a1 0.126 0.288 
b1 0.141 0.297 
c1’ 0.126 0.292 
a1* b1 0.018 0.022 
Medium Effect Size   
a1 0.322 0.942 
b1 0.361 0.967 
c1’ 0.322 0.970 
a1* b1 0.116 0.835 
Large Effect Size   
a1 0.456 0.999 
b1 0.510 1.00 
c1’ 0.456 1.00 
a1* b1 0.233 0.999 
Note. a1 = path from independent variable to mediator; b1 = path from mediator to dependent 
variable; c1’ = path from independent variable to dependent variable (direct effect); a1* b1 = 
indirect effect of the mediator. 
 
Study 3 Results 
Participants 
Of the 88 clients used in the analysis, 63.64% were female, 79.55% Caucasian, and 5.68% 
Hispanic. Approximately 34.09% of clients were single and 36.36% were married. Sixty six 
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percent of clients were not employed at the time of recruitment to the study, and 3.40% identified 
as students. Sixteen percent of clients had completed some high school, 34.09% had completed 
high school, and 29.55% had completed some college. The remaining 14.77% of clients had 
completed college or held advanced degrees (Associate’s, Bachelor’s, Master’s, Medical 
Doctorate, Juris Doctorate, or Doctorate of Philosophy). See demographics and site distribution 
tables below (Table 29 and 30) for more information on participants. 
Table 29. Study 3 client demographics (N = 88). 
Demographic Variable Number of Clients (%) 
Gender  
Female 56 (63.64%) 
Male 32 (36.36%) 
Race  
Caucasian 70 (79.55%) 
African American 14 (15.91%) 
Asian American/Pacific Islander 3 (3.41%) 
Native American/Alaskan Native 1 (1.14%) 
Ethnicity  
Hispanic/Latino 5  (5.68%) 
Not Hispanic/Latino 57 (64.77%) 
Missing 26 (29.55%) 
Sexual Orientation  
Heterosexual 79 (89.77%) 
Homosexual 6 (6.82%) 
Bisexual 1 (1.14%) 
Missing 2 (2.27%) 
Relationship Status  
Single and not dating 30 (34.09%) 
Dating 6 (6.82%) 
Cohabitating/living with partner 3 (3.41%) 
Engaged 4 (4.55%) 
Married 32 (36.36%) 
Separated 2 (2.27%) 
Divorced 11 (12.50%) 
Education Level  
Some high school 14 (15.91%) 
Completed high school/GED 30 (34.09%) 
Some college 26 (29.55%) 
Completed college 5 (5.68%) 
Advanced degree (M.A, J.D., M.D., Ph.D) 13 (14.77%) 
Student Status  
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Student 3 (3.41%) 
Non-Student 84 (95.45%) 
Missing 1 (1.14%) 
Employment Status  
Employed 30 (34.09%) 
Unemployed 58 (65.91%) 
 
Table 30. Study 3 client site distribution (N = 88). 
Site Number Number of Clients (%) 
1 13 (14.77%) 
2 26 (29.55%) 
3 6 (6.82%) 
4 11 (12.50%) 
5 10 (11.36%) 
6 2 (2.27%) 
7 1 (1.14%) 
8 11 (12.50%) 
9 3 (3.41%) 
10 5 (5.68%) 
 
Missing Data 
No missing data was present for total sessions attended, session one adherence scores, or 
baseline PHQ-9 scores as all enrolled, new clients provided baseline PHQ-9 data and clients 
without any adherence or session-by-session data were not included in the sample. Twenty-five 
clients (28.4%) did not provide week 12 PHQ-9 scores. Seventy-one clients (80.7%) did not have 
adherence data for session two, either because they failed to attend session two or because the 
clinician did not enter the PHQ-9 data into the EHR. No missing data was present for the control 
variables of interest (client gender, race, and education). The missing week 12 PHQ-9 scores were 
imputed using the procedures highlighted in the general methods section in order to avoid listwise 
deletion of cases. 
Data Distribution 
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All variables of interest (Baseline PHQ-9 Score, Week 12 PHQ-9 Score, Session 1 
Adherence Score, and total sessions attended) were positively skewed. It is of note that the session 
1 adherence scores are skewed in the direction of “0”, suggesting infrequent use of the PHQ-9 at 
clients’ first therapy sessions.  
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Figure 7. Distributions of total sessions attended, session one adherence scores, baseline PHQ-9 
scores, and Week 12 PHQ-9 scores. 
 
Table 31. Skewness statistics for continuous variables explored in mediation models.  
Baseline PHQ-9 0.02 
Week 12 PHQ-9  0.30 
Total Sessions            0.77 
S1 Adherence Score 1.32 
 
Table 32. Kurtosis statistics for continuous variables of interest. 
Baseline PHQ-9 2.17 
Week 12 PHQ-9  2.65 
Total Sessions            3.00 
S1 Adherence Score 3.72 
 
Descriptive Statistics – Client Depression Symptoms (PHQ-9 Scores) 
 Descriptive statistics were explored for client depressive symptoms measured with the 
PHQ-9. Clients (N = 88) reported clinically significant depressive symptoms at baseline (M = 
17.28, SD = 4.36, Range = 7 - 26). The majority of clients (72.73%) endorsed moderately severe 
to severe symptoms according to PHQ-9 severity score cutoffs (see Table 33). However, week 12 
PHQ-9 scores noted a reduction (see Table 34) in symptoms with a large effect size (M = 11.55, 
SD = 6.39, Range = 0 – 27, d = 1.05), with slightly over half of clients (51.15%) endorsing minimal 
to moderate depression symptoms after 12 weeks of treatment. It is important to note that there 
were no differences between those who did (i.e. an adherence score of at least “1”) or did not (i.e. 
an adherence score of “0”) receive MBC at session one with respect to baseline or week 12 
depression symptoms, suggesting similar client depression severity levels regardless of MBC 
adherence. Both clients who received and did not receive MBC at session one demonstrated 
reductions in symptoms with large effect sizes (see Tables 35 and 36).  
 
Table 33. Frequencies of PHQ-9 scores at baseline and week 12 for clients (N = 88). 
Depression Severity Baseline Week 12 
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N (%) N (%) 
Minimal Depression 
(PHQ-9 Score = 1 - 4) 
0 (0.00%) 8 (9.09%) 
Mild Depression 
(PHQ-9 Score = 5 - 9) 
1 (1.14%) 14 (15.91%) 
Moderate Depression 
(PHQ-9 Score = 10 - 14) 
23 (26.14%) 23 (26.14%) 
Moderately Severe 
(PHQ-9 Score = 15 - 19) 
34 (38.64%) 10 (11.36%) 
Severe Depression 
(PHQ-9 Score = 20 - 27) 
30 (34.09%) 8 (9.09%) 
Missing Data 0 (0.00%) 25 (28.41%) 
 
Table 34. Mean differences across baseline and week 12 PHQ-9 scores for full sample of 88 
clients. 
 M (SD) t p value Average Mean 
Difference 
Cohen’s d 
Baseline PHQ-9 
vs. 
17.28 
(4.36) 
7.24 0.000**** 5.51 1.05 
Week 12 PHQ-9 11.55 
(6.39) 
    
Note. ****p<0.0001. 
Table 35. Mean differences in baseline and week 12 PHQ-9 severity for clients who did (score 
> 0, N = 37) or did not (score = 0, N = 51) receive MBC adherence. 
 M (SD) t p value Cohen’s d 
No Adherence Baseline PHQ-9  17.61 (4.43) -0.83 0.41 0.18 
Adherence Baseline PHQ-9 16.83 (4.29)    
     
No Adherence Week 12 PHQ-9 11.60 (5.71) -0.06 0.95 0.02 
Adherence Week 12 PHQ-9 11.50 (7.08)    
 
Table 36. Mean differences across treatment for clients who did (score > 0) or did not (score = 
0) receive MBC adherence. 
 M (SD) t p value Average Mean 
Difference 
Cohen’s d 
No Adherence (N = 51)      
Baseline PHQ-9 vs. 17.61 (4.43) -5.73 0.000**** 5.98 1.18 
Week 12 PHQ-9 11.60 (5.71)     
Adherence (N = 37)      
Baseline PHQ-9 vs. 16.83 (4.29) -4.52 0.000**** 5.05 0.91 
Week 12 PHQ-9 11.50 (7.08)     
Note. ****p<0.0001. 
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Descriptive Statistics – MBC Adherence and Total Sessions Attended 
 Clients attended an average of 3.11 total therapy sessions (SD = 1.85, Range = 1 – 8).  At 
session one, clinicians’ average MBC adherence scores were 0.66 (SD = 0.93, Range = 0 – 3). 
Clinicians’ average session one and session two adherence scores remained comparable to session 
one with a mean of 0.68 (SD = 0.93, Range = 0 – 3). Fifty eight percent of clients did not receive 
any MBC at session one (i.e. an adherence score of “0”), therefore only 42% received any MBC 
(i.e. an adherence score of “1”, “2”, or “3”). This pattern remained consistent when looking at 
adherence scores across sessions one and two, as only 44.30% of clients received any MBC (see 
Table 38). Even when clinicians did use MBC in session, frequency counts of adherence scores 
suggest that very few clinicians reported viewing or discussing the PHQ-9 (i.e. scores of “2” or 
“3”) in session one (see Table 39).  
Table 37. Means and standard deviations for MBC adherence scores for early therapy sessions. 
Variable Name Mean(SD) 
Total Sessions 3.11 (1.85) 
S1 Adherence Score  0.66 (0.93) 
S2 Adherence Score 0.71 (1.05) 
Average S1/S2 Adherence Score 0.68 (0.93) 
 
Table 38. Frequency counts for clients receiving no MBC (adherence score = 0) versus some 
MBC (adherence score > 1) across sessions one and two. 
Variable Name Frequency (%) 
Adherence at S1 37 (42.00%) 
No Adherence at S1  51 (58.00%) 
Adherence at S1 or S2 39 (44.30%) 
No Adherence at S1 or S2 49 (55.70%) 
 
Table 39. Session one MBC adherence score frequencies. 
Adherence Score Frequency (%) 
Session 1  
0 52 (59.09%) 
1 23 (26.14%) 
2 7 (7.95%) 
3 7 (7.95%) 
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Session 2  
0 10 (11.36%) 
1 4 (4.54%) 
2 1 (1.14%) 
3 2 (2.27%) 
NA 71 (80.68%) 
Descriptive statistics were also calculated to identify the frequency with which clinicians 
were adhering to MBC across all sessions attended by clients (see Table 40). These percentages 
were computed by dividing the total number of sessions receiving an adherence score of “1”, “2”, 
or “3” by the total number of sessions attended by each client. For example, consider a client who 
attended five total sessions and the clinician administered PHQ-9’s at the first three sessions (i.e. 
adherence score of “1”), administered and reviewed the scores at the fourth session (i.e. adherence 
score of “2”), and did not use the PHQ-9 at the fifth session. In this case the client would receive 
an overall PHQ-9 adherence percentage of 80% (adherence greater than “0” at four out of five 
sessions), an administration adherence percentage of 60%, an administration and review adherence 
percentage of 20% and an administration, review, and discussion percentage of 0%. 
Table 40. Average percentage of attended sessions with adherence scores ranging from 0-3. 
MBC Adherence Average % of sessions attended 
Adherence score > 0 46.59% (Range = 0% - 100%) 
Adherence score = 1 28.39% (Range = 0% - 100%) 
Adherence score = 2 8.55% (Range = 0% - 100%) 
Adherence score = 3 9.93% (Range = 0% - 100%) 
 
Descriptive Statistics – Correlations Among PHQ-9, Adherence, and Sessions Attended 
 Correlations were then explored among baseline PHQ-9 scores, week 12 PHQ-9 scores, 
session one adherence scores, average session one/session 2 adherence scores, and total sessions 
attended. Variables of interest did not correlate (see Table 41). However, the correlation between 
average session one and session two adherence and baseline PHQ-9 trended toward significance 
(p = 0.097). 
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Table 41. Correlations among continuous variables of interest.  
 Baseline 
PHQ-9 
Week 12 
PHQ-9 
Total 
Sessions 
S1 Adherence 
Score 
Average S1/S2 
Adherence 
Baseline PHQ-9 1.00 0.39** -0.07 -0.17 -0.18† 
Week 12 PHQ-9 - 1.00 0.03 -0.10 -0.13 
Total Sessions - - 1.00 -0.03 -0.002 
S1 Adherence 
Score  
- - - 1.00 0.98** 
S2 Adherence 
Score 
- - - - 1.00 
Note. † p > 0.05 but < 0.10; *p<0.05; **p<0.001. 
 
Evaluating Need for Model Nesting 
Need for nesting within clinicians. Intra-class correlations (ICCs) were explored to 
determine the variances in the dependent, independent, and mediator variables to be explored (i.e. 
Week 12 PHQ-9 Scores, total number of sessions attended) due to clients being nested within 
clinicians. All 88 clients were nested within 39 clinicians, with an average of 2.26 clients per 
clinician (Range = 1 client to 7 clients per clinician). Week 12 PHQ-9 ICC was 0.056, baseline 
PHQ-9 was 0.114, total sessions attended was 0.215, and session one adherence score was 0.467. 
These ICC values corresponded to design effects of 1.07, 1.14, 1.27, and 1.59, respectively. Given 
that the design effects are less than two, recommendations from (Muthen & Satorra, 1995)  suggest 
that the modeling procedures do not need to account for variance due to between clinician effects.  
 Need for nesting within sites. ICC values were then explored to determine the variances 
in the dependent, independent and mediator variables due to clients being nested within sites. The 
88 clients were nested in one of 10 sites, with an average site size of 8.8 clients (Range = 1-26). 
The ICC value was 0.061 for baseline PHQ-9 score, 0.008 for week 12 PHQ-9 score, 0.136 for 
total sessions attended, and 0.23 for session one adherence score. Baseline PHQ-9, week 12 PHQ-
9, and total sessions attended all had ICC values with design effects less than two (1.48, 1.06, and 
1.98, respectively with nc = 8.8). However, adherence score design effects were greater than two, 
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(DEFF = 2.79), suggesting that modeling procedures do need to account for variance due to 
between site effects.   
Regression Models Accounting for Nesting 
 Simple regression models were then explored to identify additional predictors of week 12 
PHQ-9 scores and total session attendance (two dependent variables to be explored in mediation 
analysis) in order to explore potential control variables for the mediation models. Each predictor 
was explored in a separate model and all models were two-level models accounting for nesting 
due to site.  Baseline PHQ-9 score was the only predictor of week 12 PHQ-9 scores (B = 0.277, p 
= 0.007), with the result in the expected direction (i.e. higher baseline PHQ-9 predicted higher 
week 12 PHQ-9). Race was a predictor of total sessions attended (B = -1.553, p = 0.000). Compared 
to white clients, non-white clients attended 1.553 fewer clinical sessions on average. Gender (B = 
0.664, p = 0.069) and years of school (B = 0.184, p = 0.095) trended toward being predictors of 
total sessions attended. Compared to male clients, female clients appeared to attend an average of 
0.644 additional sessions. Additionally, higher years of schooling predicted higher session 
attendance such that a one unit increase in years of schooling led to an increase of 0.184 sessions 
attended on average. Baseline PHQ-9, gender, race, and years schooling were included as control 
variables in all mediation models explored below given the associations among these variables and 
the dependent variables of interest (week 12 PHQ-9 and total sessions attended). 
Table 42. Two level simple regression models with each predictor included in a separate model. 
Variable B Standard 
Error 
t-statistic p value R2 p value 
DV = Week 12 PHQ-9      
Baseline PHQ-9 0.287 0.103 2.696 0.007** 0.078 0.180 
Session 1 Adherence -0.748 0.696 -1.074 0.283 0.015 0.500 
Average S1/S2 
Adherence 
-0.943 0.591 -1.595 0.111 0.022 0.330 
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Moderated Mediation Model 1 – Session 1 Adherence  
 A moderated mediation model was then fit to evaluate path estimates controlling for 
baseline PHQ-9, gender, race, and years of school. The first model explored was a moderated 
mediation model with an independent variable of session one adherence, a mediator variable of 
total sessions attended, and a dependent variable of week 12 PHQ-9 score. Session one adherence 
was also evaluated as a moderator of the relation between total sessions and week 12 PHQ-9 to 
determine if zero (score of “0”), moderate (score of “1”), or high levels (score of “2” or “3”) of 
MBC adherence had a differential impact on the effectiveness of sessions attended for reducing 
depression symptoms. See Figure 8 below for an overview of the model and paths to be estimated. 
Session 1 
Dichotomous 
Adherence 
0.186 2.175 0.085 0.932 0.003 0.889 
Total Sessions 0.026 1.940 0.014 0.989 0.002 0.969 
Gender -1.234 2.428 -0.508 0.611 0.012 0.740 
Race 0.231 6.487 0.036 0.972 0.000 0.977 
Years of School -0.183 0.360 -0.509 0.611 0.004 0.796 
DV = Total Sessions      
Session 1 Adherence 0.020 0.178 0.110 0.912 0.000 0.956 
Average S1/S2 
Adherence 
0.077 0.166 0.464 0.643 0.002 0.813 
Session 1 
Dichotomous 
Adherence 
0.225 0.338 0.665 0.506 0.004 0.734 
Gender 0.664 0.365 1.819 0.069† 0.034 0.337 
Race -1.553 0.230 -6.763 0.000*** 0.035 0.000*** 
Years of School 0.184 0.110 1.669 0.095† 0.048 0.365 
Note. † p > 0.05 but < 0.10; **p < 0.01; ***p < 0.001. 
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Figure 8. Moderated mediation model 1 with session one adherence moderating the relation 
between total sessions attended and week 12 PHQ-9 Scores. S1 Adher = session one adherence; 
Total Sess = total sessions attended; W12 PHQ = Week 12 PHQ-9 Score.
As anticipated from the correlation and regression results, there were no direct indirect, or 
moderating effects that emerged from the estimation of the model. All relations among variables 
were quite small, suggesting that MBC adherence at session one was not a predictor of depression 
symptom scores at week 12, and total sessions attended had no impact on this relation as a mediator 
variable. As noted above, however, the study was not powered to detect small effect sizes, which 
may have limited the identification of a mediating effect.  
Table 43. Path estimates for mediation model 1. 
Path Estimate Standard Error t statistic p value 
a1 -0.106 0.160 -0.663 0.508 
b1 0.731 0.648 1.128 0.259 
c1’ (direct effect) 1.278 1.915 0.668 0.504 
c2’ (interaction) -0.509 0.462 -1.103 0.270 
Note.  a1 = relation between total sessions and session 1 adherence; b1 = relation between week 
12 PHQ-9 score and total sessions; c1’ = direct effect of session 1 adherence on week 12 PHQ-
9 score; c2’ = interaction effect of session 1 adherence and total sessions on week 12 PHQ-9 
scores (moderated mediation effect). 
There were also no conditional indirect effects in the estimated model (see Table 44 below), 
suggesting that the relation between week 12 PHQ-9 scores and total sessions was not moderated 
by level of clinician MBC adherence at session one. 
a1 b1 
c1’
c2’
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Table 44. Conditional indirect effects for mediation model 1. 
 Estimate Standard Error t statistic p value 
No Adherence 
(Score = 0) 
-0.077 0.135 -0.571 0.568 
Medium 
Adherence 
(Score = 1) 
-0.023 0.061 -0.383 0.702 
High Adherence 
(Score = 2 or 3) 
0.003 0.048 0.071 0.943 
  
Moderated Mediation Model 2 –Average Session 1 and Session 2 Adherence 
 An alternative moderated mediation model was explored with an independent variable of 
average session one and session two adherence, a mediator of total sessions attended, a dependent 
variable of week 12 PHQ-9, and controlling for baseline PHQ-9 score, education level, race, and 
gender (see Figure 9 below).  
 
Figure 9. Moderated mediation model 2 with average session one and session two adherence 
moderating the relation between total sessions attended and week 12 PHQ-9 Scores. Avg Adher = 
average session one and session two adherence; Total Sess = total sessions attended; W12 PHQ = 
Week 12 PHQ-9 Score. 
 
 As in moderated mediation model one, there were no direct or indirect effects with the 
change in independent variable from session one adherence alone to average session one and 
c2’ 
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session two adherence. There were also no conditional indirect effects for zero, medium, or high 
average session one and session two adherence. 
Table 45. Path estimates for mediation model 2. 
Path Estimate Standard Error t statistic p value 
a1 -0.040 0.138 -0.288 0.773 
b1 0.605 0.576 1.050 0.294 
c1’ (direct effect) 0.709 1.676 0.423 0.672 
c2’ (interaction) -0.363 0.409 -0.887 0.375 
Note.  a1 = relation between total sessions and session 1 adherence; b1 = relation between week 
12 PHQ-9 score and total sessions; c1’ = direct effect of session 1 adherence on week 12 PHQ-
9 score; c2’ = interaction effect of session 1 adherence and total sessions on week 12 PHQ-9 
scores (moderated mediation effect). 
 
Table 46. Conditional indirect effects for mediation model 2. 
 Estimate Standard Error t statistic p value 
No Adherence  
(Score = 0) 
-0.024 0.093 -0.259 0.796 
Medium 
Adherence  
(Score = 1) 
-0.010 0.045 -0.212 0.832 
High Adherence 
(Score = 2 or 3) 
-0.002 0.030 -0.079 0.937 
  
Moderated Mediation Model 3 – Dichotomous Adherence Variable  
 Given the significant percentage of clinicians not using MBC at session one (i.e. adherence 
scores of “0”), a third moderated mediation model was explored with a dichotomous independent 
variable coded “1” if clients received at least some MBC adherence (score of “1”, “2”, or “3”) at 
session one or “0” if they did not receive any MBC at session one (MBC adherence score of “0”; 
see Figure 10). 
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Figure 10. Moderated mediation model 3 with dichotomous adherence variable moderating the 
relation between total sessions attended and week 12 PHQ-9 Scores. 0/1 Adher = dichotomous 
adherence; Total Sess = total sessions attended; W12 PHQ = Week 12 PHQ-9 Score. 
 
As observed above, there were no direct or indirect effects, suggesting no relation between 
dichotomous session one adherence and week 12 PHQ-9 and no mediating effect of total number 
of sessions. There were also no conditional indirect effects, suggesting that the relation between 
total sessions and week 12 PHQ-9 score is not moderated by adherence level (i.e. adherence of “0” 
or “1”). 
Table 47. Path estimates for mediation model 3. 
Path Estimate Standard Error t statistic p value 
a1 0.057 0.291 0.195 0.845 
b1 0.565 0.590 0.958 0.338 
c1’ (direct effect) 2.207 2.821 0.782 0.434 
c2’ (interaction) -0.432 0.674 -0.641 0.522 
Note.  a1 = relation between total sessions and session 1 adherence; b1 = relation between week 
12 PHQ-9 score and total sessions; c1’ = direct effect of session 1 adherence on week 12 PHQ-
9 score; c2’ = interaction effect of session 1 adherence and total sessions on week 12 PHQ-9 
scores (moderated mediation effect). 
  
Table 48. Conditional indirect effects for mediation model 3. 
 Estimate Standard Error t statistic p value 
No Adherence  
(Score = 0) 
0.032 0.213 0.150 0.880 
Adherence  
(Score = 1) 
0.008 0.074 0.102 0.919 
c2’ 
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Exploratory Analyses – Direct Effect of Adherence on Outcomes for High and Low 
Attending Clients 
 Given the lack of moderated mediation, exploratory analyses were performed to determine 
whether clients with “low” session attendance (total sessions less than or equal to two) and clients 
with “high” session attendance (total sessions greater than two) demonstrated differences in 
depression symptom outcomes or differences in the relation between session one adherence and 
week 12 PHQ-9 scores. Both low (N = 41) and high attendance (N = 47) clients demonstrated 
statistically and clinically significant improvement in depression symptoms across 12 weeks of 
treatment. High and low attendance clients did not have differences in week 12 outcomes, with 
both groups of clients having moderate depression symptoms at week 12. 
Table 49. Mean differences across treatment for low (N = 41) and high (N=47) attendance 
clients.  
 M (SD) t p value Average 
Mean 
Difference 
Cohen’s d 
Low Attendance (N = 41)      
Baseline PHQ-9 vs. 17.91(4.58) -3.97 0.001** -5.63 1.07 
Week 12 PHQ-9 11.46(7.16)     
High Attendance (N = 47)      
Baseline PHQ-9 vs. 16.73(4.14) -6.27 0.000*** -5.43 1.00 
Week 12 PHQ-9 11.61(5.93)     
Note.  **p < 0.01; ***p < 0.001. 
Table 50. Mean differences in week 12 PHQ-9 outcomes for low (N = 41) and high (N=47) 
attendance clients. 
 M(SD) t p value Cohen’s d 
Low Attendance Week 12 
PHQ-9 
11.46(7.16) -0.08 0.93 0.02 
High Attendance Week 12 
PHQ-9 
11.61(5.93)    
 
Session one adherence did not predict PHQ-9 outcomes for either the low or high 
attendance clients. Compared to white clients, non-white clients who were high attenders had 
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slightly lower week 12 PHQ-9 scores. No other relations were observed among variables, 
suggesting that adherence was not a predictor of outcomes, regardless of number of sessions 
attended by clients. 
Table 51. Predictors of outcome (Week 12 PHQ-9) for low attendance clients (N = 41). 
Predictor Estimate Standard 
Error 
t 
statistic 
p value R2 p value 
DV: Week 12 PHQ-9       
Baseline PHQ-9 0.557 0.152 3.673 0.000*** 0.149 0.046* 
Gender -1.739 3.622 -0.480 0.631   
Race 1.483 1.876 0.790 0.429   
Years Education -0.213 0.424 -0.502 0.616   
Session 1 Adherence -0.100 1.147 -0.087 0.930   
Note.  *p < 0.05; ***p < 0.001. 
 
Table 52. Predictors of outcome (Week 12 PHQ-9) for high attendance clients (N = 47). 
Predictor Estimate Standard 
Error 
t statistic p value R2 p value 
DV: Week 12 PHQ-9       
Baseline PHQ-9 0.428 0.162 2.642 0.008** 0.269 0.035* 
Gender -0.015 0.141 -0.106 0.915   
Race -0.083 0.022 -3.731 0.000***   
Years Education -0.114 0.100 -1.150 0.250   
Session 1 Adherence -0.121 0.112 -1.085 0.278   
Note.  *p < 0.05; **p < 0.01; ***p < 0.001.    
 
Study 3 Discussion 
Contrary to initial hypotheses, although clients demonstrated reductions in depression 
symptoms across 12 weeks of psychotherapy, there was no direct effect of early session adherence 
to MBC (session one or average session one and session two) on week 12 PHQ-9 scores when 
controlling for client baseline PHQ-9, gender, race, and years of education. Increased session 
attendance also failed to mediate the relation between clinician MBC adherence at therapy session 
one (independent variable) and client symptom outcomes (dependent variable) (H1), though the 
study was underpowered to detect paths with small effect sizes. Additionally, clinician MBC 
 104 
adherence was not a moderator of the relation between session attendance and client outcomes 
(H2).  
It is perhaps surprising that MBC adherence did not have a direct effect on symptoms given 
the strong evidence for MBC’s effectiveness in enhancing depression outcomes (Scott & Lewis, 
2014). However, further exploration of clinician’s MBC adherence showed that clients attended 
very few sessions (M = 3.11) and clinicians often failed to use MBC in those sessions. Only 46% 
of attended client sessions included any MBC (i.e., at least administering the PHQ-9), and only 
9% of sessions attended by clients included clinician review and/or discussion of the PHQ-9 
scores, elements that seem to truly enhance the effect of MBC (Lambert et al., 2003). Bickman 
and colleagues (2016) highlighted the potential for a dose-response relation between MBC and 
symptoms, thereby suggesting that a certain amount of clinician MBC use both within and across 
therapy sessions is needed in order to achieve change. The overall low adherence to MBC early in 
therapy found in this study may explain why early MBC was not associated with outcomes. This 
low adherence may be partially due to the design of the R01 parent study, as the parent study 
sought to identify whether and how much clinicians opted to implement MBC and therefore did 
not incorporate methods to ensure adherence occurred for mediation testing. Future research is 
needed to identify the level of MBC adherence required to achieve enhanced depression symptom 
change in order to more formally test moderated mediation effects with an adequate dosage of 
MBC intervention. In specific, additional evaluation is needed to determine when in treatment, 
how frequently, and what level of MBC adherence is optimal in order to maximize symptom 
change. 
Modern approaches to mediation diverge from the traditional Baron and Kenny (Baron & 
Kenny, 1986) approach and suggest that a direct effect is unnecessary to explore mediation (Hayes, 
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2013).  As a result, mediation models were explored in this study to determine the potential role 
of enhanced treatment engagement (via number of sessions attended) as a mechanism of action of 
MBC. Session attendance did not emerge as a mediator, suggesting that the data did not support 
enhanced treatment engagement as a mechanism, at least in how it was operationalized in this 
study. The failure to identify a direct effect may be due to the limited application of MBC across 
sessions. However, clients who only attended a maximum of two sessions demonstrated 
comparable depression symptom change to clients who attended more than two sessions. While 
evidence suggests that early attrition from psychotherapy leads to poor outcomes for clients (Cahill 
et al., 2003; Simpson et al., 1995), findings from this study suggest that a high dosage of 
psychotherapy and MBC may not be necessary for some clients to achieve clinically significant 
change. It may be the case that some clients benefit from very brief psychotherapy (i.e. one or two 
sessions). Although literature supports greater client benefit from shorter term psychotherapy 
(Cuijpers, Huibers, Ebert, Koole, & Andersson, 2013) and a “sudden gains” phenomenon in which 
many clients exhibit clinically significant change early in treatment (Busch, Kanter, Landes, & 
Kohlenberg, 2006), few studies have explored whether one or two sessions of psychotherapy is 
enough for some clients to achieve symptom change. Some evidence suggests that there may be 
two groups of clients who drop out early from treatment: one group with severe symptoms and 
significant barriers to treatment attendance (Barrett, Chua, Crits-Christoph, Gibbons, & 
Thompson, 2008) and one group with early symptom improvement or remission (Krishnamurthy, 
Khare, Klenck, & Norton, 2015; Lutz et al., 2009). Given the high demands for depression services 
and low client attendance in community mental health care, further exploration is warranted to 
evaluate the utility of very brief psychotherapy, perhaps guided by MBC to select optimal 
treatment targets and identify clients most likely to benefit from brief treatment. 
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The findings highlighted in this study may also be due to total session attendance not being 
the most appropriate indicator of treatment engagement. Alternatively, enhanced treatment 
engagement may not be a mechanism of action of MBC. Per the former, treatment engagement is 
also comprised of client participation in session and clinician-client alliance (Lindsey et al., 2014), 
two indicators that were not measured in this study and may require additional exploration as 
possible mediators of MBC’s effectiveness. Per the latter, it may be the case that other putative 
mechanisms of action such as enhanced client symptom understanding (Dowrick et al., 2009), 
more accurate assessment (Sapyta et al., 2005), and/or enhanced “dosage” of psychotherapy 
interventions (Wolpert et al., 2016) may better explain how MBC produces symptom change in 
depression. Overall, treatment engagement, as well as the other putative mechanisms highlighted 
above, warrant further exploration as potential mediators of the relation between therapist MBC 
adherence and depression outcomes. 
There are also several issues related to therapist MBC adherence that may have influenced 
the findings presented in this study. Although adherence serves as a measure of clinician 
application of MBC, it does not capture how well a clinician actually uses MBC in each clinical 
session (i.e. MBC competence; Schoenwald et al., 2011). Competence in using MBC may 
ultimately be more important for enhancing clinical outcomes, and should therefore be explored 
as a measure of overall MBC fidelity. Additionally, this study utilized early session measures of 
MBC adherence as an independent variable in the mediation model in order to ensure that the 
adherence measure preceded the majority of treatment sessions attended and depression symptom 
change given the putative mediator under investigation. MBC adherence may actually be more 
important at later sessions, perhaps as a tool to address a client’s lack of progress in ongoing 
treatment or to signal a need for treatment changes (Lambert et al., 2003; Simon et al., 2012). It 
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may be important for future research to employ more sophisticated cross-lagged panel mediation 
models in order to identify when depression symptom change occurs, when MBC adherence might 
be most important (i.e. at what therapy sessions), and how MBC adherence works to produce 
change across multiple time points (Preacher, 2015).  
Limitations  
As noted above, one of the biggest limitations of this study was its small sample size. The 
study was underpowered to identify estimates with small effect sizes for the early session 
adherence to mediator path (path a1), as path estimates were below 0.12 in all models (see power 
analysis in Study 3 Methods). The sample explored in this study (N = 88 clients) was also not 
sufficiently powered to detect mediation effects with small effect sizes, therefore the analysis may 
have failed to identify indirect effects. Future research should explore total sessions attended as a 
putative mediator and mechanism of action of MBC with greater MBC adherence as well as a 
larger client sample size to increase statistical power.  
This study also only included clients enrolled from 10 of the 12 sites recruited in the parent 
R01 study. All mediation analyses will be rerun with the full sample of new, enrolled clients across 
all 12 sites as additional data becomes available in the ongoing parent study. Additionally, this 
study explored only the first 12 weeks of therapy for new clients who enrolled in the parent R01 
study at 10 community behavioral health sites. As a result, the sample of clients explored in this 
study may not generalize to other clients across other mental health treatment settings.  
Conclusions 
This study sought to evaluate whether enhanced session attendance served as a mechanism 
of action of MBC’s ability to enhance depression symptom change. The mediation models 
explored in this study failed to identify an association between MBC adherence in early treatment 
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sessions and improved depression outcomes and did not find evidence for session attendance as a 
mechanism of action of MBC. However, all clients demonstrated clinically significant 
improvement in depression symptoms across 12 weeks of treatment regardless of client MBC 
adherence in the first two sessions or level of session attendance. These results may have important 
implications for guiding future research with larger sample sizes of clients in order to identify both 
the level of MBC adherence needed to enhance depression symptom change as well as to enable 
further testing of enhanced session attendance and other putative mechanisms of action of MBC. 
Additionally, these study findings suggest a need for further research exploring how a subset of 
clients experience clinically significant change early in care (one or two sessions). In sum, the 
study results presented herein serve as a first step in testing MBC’s mechanisms of action in order 
to understand key MBC components and maximize the effect of MBC on depression for clients 
across settings. 
General Discussion 
 MBC is a potentially powerful EBP that could serve as a minimal intervention needed to 
produce change and begin to reduce the global burden of disease association with depression 
(Glasgow et al., 2014; Organization, 2016). The studies presented herein were some of the first, to 
our knowledge, to understand clinician in-session responses to MBC feedback, to evaluate patterns 
of clinician use of MBC in community mental health settings, and to formally test one putative 
MBC mechanism of change. Overall study findings suggest that clinicians generally respond to 
feedback in line with the FIT model, but that the complexities of clinician assessment and decision-
making processes and client responses to feedback may warrant additional exploration. There also 
appear to be observable patterns of clinician MBC adherence post training, and that clinicians 
demonstrate substantial variation in their use of MBC in session. In specific, there appears to be at 
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least two common patterns of MBC use among community clinicians: those who start high and 
maintain their use and those who start low and decrease their use over time. However, the studies, 
though underpowered to detect some relations, failed to identify treatment engagement as a 
mechanism of change for MBC. The dosage of MBC required to produce symptom change also 
remains unclear.  
Additional research is needed to elucidate MBC’s key components and causal processes in 
order to maximize MBC’s effective implementation in community settings. In specific, broader 
evaluations of fidelity that include clinician adherence, competence, and differentiation may be 
helpful for identifying when and how MBC produces symptom change. Additional person-
centered analyses may also be useful to integrate both qualitative exit interview and quantitative 
adherence data such that class differences in in-session MBC use could be identified. This 
approach may provide further context for why MBC adherence failed to be associated with 
depression symptom outcomes. Finally, all three studies presented herein could have benefitted 
from a larger sample size and more complete data. Better quality data at the client-level could 
enable greater variation in clinician exit interview responses to receiving feedback, higher potential 
for identifying additional classes of clinicians with unique patterns of MBC use, and greater power 
to detect mediation. A larger sample size could also enable the use of sophisticated longitudinal 
cross-lagged panel mediation testing, thereby identifying whether and when in treatment putative 
mechanisms such as treatment engagement have the greatest impact on the relation between MBC 
use and depression symptom change.  
Next Steps and the Future of MBC Research 
 Recent literature has suggested that mental health care is at a “tipping point” such that the 
wide availability of measures and benefits of MBC are likely to tip mental health practice toward 
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the regular use of MBC. In fact, not using MBC has been presented as a disservice to both the 
clients who serve to benefit as well as the organizations and health care systems who base their 
quality assurance and treatment offering decisions on treatment effectiveness data (Fortney et al., 
2016). Priority has been placed on developing brief, psychometrically validated self-report 
measures as well as advanced technological solutions via user-centered design approaches for 
maximizing the reach and feasibility of MBC implementation (Fortney et al., 2016; Lyon & Lewis, 
2016). Additionally, MBC is marketed as an EBP that is efficient to use in session and requires 
less burden on clinicians with respect to cost, resources, and training requirements when compared 
to complex treatments like Cognitive Behavioral Therapy (CBT; Scott & Lewis, 2014). In sum, 
the conditions appear ripe for rapid uptake of MBC practices across settings, yet successful 
community implementation remains challenging and much is still unknown about the key 
components of MBC that will maximize outcomes. 
 Despite MBC’s lower complexity compared to CBT and other EBPs, it is not without its 
challenges with respect to training and implementation. In fact, clinicians highlight many of the 
same barriers to MBC use that they have with more complex EBPs, including time limitations, 
lack of quality training, limited ongoing supervision, and few resources (including technology; 
Scott & Lewis, in prep). Many of these clinician concerns may not be unfounded, as advanced 
technological systems that facilitate MBC can be prohibitively expensive to purchase, maintain, 
and integrate with proprietary electronic health record software. Even if clinicians gain access to 
user-friendly MBC technologies, they still likely require high quality training with active learning 
strategies and ongoing supervision to maintain use with complex community clients. With these 
barriers in mind, it would seem like an insurmountable task to implement MBC in the community 
mental health settings with the most need for quality depression treatment. However, study 
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findings highlighted above note the potential for a subset of clinicians to have high, MBC use that 
is sustained over at least a 5-month period. 
 A key next step in enhancing the potential for broad reach of MBC is to learn more about 
the individuals within an organization who are high, maintaining users of MBC as identified in the 
present studies. These potential EBP champions (Kitson et al., 1998) appear to be successfully 
using MBC despite the many barriers. Leveraging the MBC skills, training background, and social 
influence of high use clinicians may be especially influential for encouraging a shift in norms 
towards broad MBC use. For example, clinics could facilitate additional MBC training 
opportunities for champions, who could then provide ongoing consultation to their colleagues 
regarding how to overcome barriers to MBC use. If clinic norms could shift to elevate the 
importance of EBPs, routine implementation of MBC would perhaps not feel so divergent from 
current practices (Gray, Joy, Plath, & Webb, 2015).  
Next, the most effective studies of MBC in both psychotherapy and pharmacotherapy 
highlight the utility of clinical decision support tools to guide clinician decision-making upon 
receipt of MBC feedback (Lambert et al., 2001; Trivedi et al., 2006). These clinical-decision 
support tools can take the form of decision trees that would guide clinicians towards appropriate 
interventions for responding to positive or negative feedback. Community clinicians may require 
additional support for both identifying an expected standard of symptom change for their clients 
and for deciding what to do in the moment when they receive feedback that an especially 
challenging client is not making progress. As highlighted by the FIT model (Kluger & DeNisi, 
1996), such support may enhance clinician motivation and self-efficacy in responding to feedback 
by trying new, evidence-based treatment approaches, even with complex clients who have failed 
to respond to previous interventions. However, additional research is needed to identify the optimal 
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standards of change and interventions to be integrated into such clinical decision support tools 
targeted for community settings.  
Finally, MBC implementation could benefit from the provision of additional resources for 
training and supervision in EBPs both in community mental health clinicians’ graduate programs 
as well as in the clinics where they are employed. The passage of the Patient Protection and 
Affordable Care Act (PPACA) has placed greater emphasis on enhancing broad access to quality 
mental health care, an initiative that aligns with the goals of the field of implementation science 
(Obama, 2016). The PPACA specifically prioritizes screening for mental health symptoms and use 
of MBC approaches in both primary care and in mental health care settings. However, there are 
still significant disparities in the availability of high quality, evidence-based mental health 
screening and care, especially for rural populations and individuals from racial or ethnic minority 
backgrounds (Alegría et al., 2008; Priester et al., 2016). Some have suggested that paraprofessional 
clinicians could be trained to meet these needs (Montgomery, Kunik, Wilson, Stanley, & Weiss, 
2010), but it is still challenging and costly to provide consistent EBP training and adequate wages 
to build a capable workforce of paraprofessional and graduate-level clinicians (Mechanic & 
Olfson, 2016). Additionally, the use of paraprofessionals would not solve the issue of medical 
doctors practicing in primary care who also require training in the use of MBC as a screening and 
monitoring tool for depression symptoms (Kearney, Wray, Dollar, & King, 2015). Until significant 
systemic changes occur to provide additional support for clinicians on the front lines of service, 
MBC and other EBP implementation efforts are likely to face significant challenges and the global 
burden of depression will likely persist. 
Conclusions 
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In sum, the studies presented herein were some of the first to elucidate how MBC functions 
in session to improve depression symptoms, with the ultimate goals of informing efforts to widely 
implement MBC and enhancing outcomes for community clients. The variation in clinician in-
session adherence to MBC over time and limited association of MBC with clinical outcomes in 
these studies suggests additional efforts are warranted to identify how much MBC is needed to 
produce change and how to encourage clinicians to successfully implement MBC at an effective 
level. If research is able to identify the core components of MBC and community mental health 
norms shift to facilitate EBP use, we may truly be at a “tipping point” for broad and effective 
appication of MBC for depression with clients most in need. 
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Appendices 
 
 
 
 
 
 
Appendix A. Study measures collected through the parent R01 study. 
Domain Measures & Indicators Interval 
Client Measures  
Demographics Developed by Lewis & Simons (2011) to assess clinician 
demographic information and training background. 
 
Baseline 
Depression  
Severity 
Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, 
& Williams, 2001). The PHQ-9 is a 9 item self-report that 
assesses depression severity and has demonstrated good 
internal consistency (α=.85-.89) and sensitivity to change 
(Löwe, Kroenke, Herzog, & Gräfe, 2004). 
All Sessions 
by Clinicians; 
Baseline and 
Week 12 by 
Research 
Staff 
 
Client 
Treatment 
Engagement 
(mediator) 
Number of sessions attended in the Centerstone EHR. Monthly EHR 
Queries 
Clinician Measures 
Demographics Developed by Lewis & Simons (2011) to assess clinician 
demographic information and training background. 
 
Baseline 
MBC 
Adherence 
A measure of MBC adherence coded as 0-did not administer, 
1-administered only, 2-administered and reviewed scored, 
and 3- administered, reviewed scores, and discussed with 
client in session – collected from the HER 
 
All Sessions 
Behavioral 
Approaches to 
MBC 
Qualitative Clinician exit interviews will be conducted with 
clinicians to identify the alignment of clinician use of MBC 
with the FIT model, to obtain details of how clinicians 
employed MBC, and to expand upon data collected from 
clients on MBC use in session.  
5 months 
following 
MBC training 
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Appendix B. List of DSM diagnostic codes for inclusion in the parent R01 study.  
293.83 
DEPRESSIVE DISORDER DUE TO ANOTHER MEDICAL CONDITION 
WITH DEPRESSIVE FEATURES 
293.83 
DEPRESSIVE DISORDER DUE TO ANOTHER MEDICAL CONDITION 
WITH MAJOR DEPRESSIVE-LIKE EPISODE 
293.83 
DEPRESSIVE DISORDER DUE TO ANOTHER MEDICAL CONDITION 
WITH MIXED FEATURES 
296.20 MAJOR DEPRESSIVE DISORDER SINGLE EPISODE UNSPECIFIED 
296.20 
MAJOR DEPRESSIVE DISORDER SINGLE EPISODE UNSPECIFIED 
DEGREE 
296.21 MAJOR DEPRESSIVE DISORDER SINGLE EPISODE MILD 
296.21 MAJOR DEPRESSIVE DISORDER SINGLE EPISODE MILD DEGREE 
296.22 MAJOR DEPRESSIVE DISORDER SINGLE EPISODE MODERATE 
296.22 
MAJOR DEPRESSIVE DISORDER SINGLE EPISODE MODERATE 
DEGREE 
296.23 MAJOR DEPRESSIVE DISORDER SINGLE EPISODE SEVERE 
296.23 
MAJOR DEPRESSIVE DISORDER SINGLE EPISODE SEVERE DEGREE 
WITHOUT MENTION OF PSYCHOTIC BEHAVIOR 
296.23 
MAJOR DEPRESSIVE DISORDER SINGLE EPISODE SEVERE WITHOUT 
PSYCHOTIC FEATURES 
296.24 
MAJOR DEPRESSIVE DISORDER SINGLE EPISODE SEVERE DEGREE 
SPECIFIED AS WITH PSYCHOTIC BEHAVIOR 
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296.24 
MAJOR DEPRESSIVE DISORDER SINGLE EPISODE SEVERE WITH 
PSYCHOTIC FEATURES 
296.24 
MAJOR DEPRESSIVE DISORDER SINGLE EPISODE WITH PSYCHOTIC 
FEATURES 
296.25 
MAJOR DEPRESSIVE DISORDER SINGLE EPISODE IN PARTIAL OR 
UNSPECIFIED REMISSION 
296.25 
MAJOR DEPRESSIVE DISORDER SINGLE EPISODE IN PARTIAL 
REMISSION 
296.26 
MAJOR DEPRESSIVE DISORDER SINGLE EPISODE IN FULL 
REMISSION 
296.30 MAJOR DEPRESSIVE DISORDER RECURRENT EPISODE UNSPECIFIED 
296.30 
MAJOR DEPRESSIVE DISORDER RECURRENT EPISODE UNSPECIFIED 
DEGREE 
296.30 MAJOR DEPRESSIVE DISORDER RECURRENT UNSPECIFIED 
296.31 MAJOR DEPRESSIVE DISORDER RECURRENT EPISODE MILD 
296.31 
MAJOR DEPRESSIVE DISORDER RECURRENT EPISODE MILD 
DEGREE 
296.31 MAJOR DEPRESSIVE DISORDER RECURRENT MILD 
296.32 MAJOR DEPRESSIVE DISORDER RECURRENT EPISODE MODERATE 
296.32 
MAJOR DEPRESSIVE DISORDER RECURRENT EPISODE MODERATE 
DEGREE 
296.32 MAJOR DEPRESSIVE DISORDER RECURRENT MODERATE 
296.33 MAJOR DEPRESSIVE DISORDER RECURRENT EPISODE SEVERE 
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296.33 
MAJOR DEPRESSIVE DISORDER RECURRENT EPISODE SEVERE 
DEGREE WITHOUT MENTION OF PSYCHOTIC BEHAVIOR 
296.33 
MAJOR DEPRESSIVE DISORDER RECURRENT SEVERE WITHOUT 
PSYCHOTIC FEATURES 
296.34 
MAJOR DEPRESSIVE DISORDER RECURRENT EPISODE SEVERE 
DEGREE SPECIFIED AS WITH PSYCHOTIC BEHAVIOR 
296.34 
MAJOR DEPRESSIVE DISORDER RECURRENT EPISODE WITH 
PSYCHOTIC FEATURES 
296.34 
MAJOR DEPRESSIVE DISORDER RECURRENT SEVERE WITH 
PSYCHOTIC FEATURES SPECIFY: MOOD-CONGRUENT 
296.35 
MAJOR DEPRESSIVE DISORDER RECURRENT EPISODE IN PARTIAL 
OR UNSPECIFIED REMISSION 
296.35 
MAJOR DEPRESSIVE DISORDER RECURRENT EPISODE IN PARTIAL 
REMISSION 
296.35 
MAJOR DEPRESSIVE DISORDER RECURRENT IN PARTIAL 
REMISSION 
296.36 
MAJOR DEPRESSIVE DISORDER RECURRENT EPISODE IN FULL 
REMISSION 
296.36 MAJOR DEPRESSIVE DISORDER RECURRENT IN FULL REMISSION 
296.80 ATYPICAL DEPRESSIVE DISORDER 
296.90 UNSPECIFIED EPISODIC MOOD DISORDER 
300.4 DYSTHYMIC DISORDER EARLY ONSET WITH ATYPICAL FEATURES 
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300.4 
DYSTHYMIC DISORDER EARLY ONSET WITHOUT ATYPICAL 
FEATURES 
300.4 DYSTHYMIC DISORDER LATE ONSET WITH ATYPICAL FEATURES 
300.4 
DYSTHYMIC DISORDER LATE ONSET WITHOUT ATYPICAL 
FEATURES 
300.4 PERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA) 
301.13 CYCLOTHYMIC DISORDER 
311 DEPRESSIVE DISORDER NOS 
311 DEPRESSIVE DISORDER NOT ELSEWHERE CLASSIFIED 
311 OTHER SPECIFIED DEPRESSIVE DISORDER 
311 UNSPECIFIED DEPRESSIVE DISORDER 
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Appendix C. FIT model for clinician responses to feedback. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MBC Feedback 
(PHQ-9 Score)
Positive -
Improvement
Change Behavior Reject Standard
Change Standard 
(Increase) Reject Feedback
Negative -
Deterioration or 
Lack of Progress
Change Behavior Reject Standard
Change Standard 
(Decrease) Reject Feedback
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Psychotherapy Integration, Washington, D.C. 
 
Schauble, L. A., Connolly Gibbons, M. B., Scott, K., Thompson, S. M., Hamilton, J. L.,  
Heintz, L. E., & Crits- Christoph, P. (2011, September). An analysis of the most common 
diagnostic discrepancies between clinical diagnoses and structured clinical interview 
diagnoses in a community mental health setting. Poster session presented at the meeting of 
the North American Society for Psychotherapy Research, Banff, Alberta.         
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Hamilton, J. L., & Crits- Christoph, P. (2011, May). Changes in CCRT patterns over  
the course of cognitive and interpersonal  therapies. Poster session presented at the  
meeting of the Society for the Exploration of Psychotherapy Integration, Washington, D.C. 
 
Clinical Training 
 
Northwestern Medicine Stone Institute of Psychiatry    2017-2018 
 Intern Clinician 
Supervisors: Dr. Mark Reinecke, Ph.D., ABPP, Dr. Vicky Singh, Ph.D., Dr. John Stutesman, 
Psy.D. 
Conducted Cognitive Behavioral Therapy and Dialectical Behavior Therapy in a community 
mental health center setting for patients with Bipolar Disorder, Severe Major Depressive 
Disorder, Anxiety Disorder, Panic Disorder, and Cluster B Personality Psychopathology. 
 
Eating Recovery Center – Insight Behavioral Health     2017-2018 
Intern Clinician  
Supervisors: Dr. Anne Kubal, Ph.D., Dr. Angela Derrick, Ph.D. 
Conducted Acceptance and Commitment Therapy and Dialectical Behavior Therapy Skills 
groups and individual therapy with adults and adolescents in Intensive Outpatient and Partial 
Hospital programs presenting with Anorexia, Bulimia, Major Depressive Disorder, Panic 
Disorder, Generalized Anxiety Disorder, Obsessive Compulsive Disorder, Posttraumatic Stress 
Disorder, and Bipolar Disorder. Conducted extensive risk assessments for patients stepping 
down from inpatient hospitalization.  
 
Indiana University Health Neuroscience Center     2016 
Practicum Clinician 
Supervisor: Dr. Courtney Johnson, Ph.D., HSPP 
Conducted cognitive and neuropsychological testing with adult and geriatric patients presenting 
with memory and psychiatric concerns, provided feedback to patients regarding testing 
outcomes, completed integrated assessment reports 
 
Indiana University – Bloomington               2014-2017 
Clinician, Cognitive Behavioral Therapy Research and Training Clinic 
Supervisors: Dr. Cara C. Lewis, Ph.D., HSPP and Dr. Brittany Brothers, Ph.D.  
Conducted Intake Assessments (SCID; ADIS: YBOCS) and Cognitive Behavioral Therapy 
Individual Sessions with clients presenting with Major Depressive Disorder, Panic 
Disorder, Generalized Anxiety Disorder, and Specific Phobia, completed integrated 
assessment reports, supervised peer CBT trainees 
 
Indiana University – Bloomington               2013-2016 
Clinician, Parent Child Clinic/Parent Behavior Training Clinic 
Supervisor: Dr. John Bates, Ph.D. 
Conducted Intake Assessments, completed school-based assessments, conducted Parent 
Behavior Training family therapy sessions for children presenting with behavior problems, 
completed functional analysis of child behavior, supervised peer PBT trainees 
 
Larue Carter Memorial Hospital – Adolescent Girls and Adult Inpatient Units   2016 
Practicum Clinician 
Supervisors: Dr. Melissa Butler, Ph.D., HSPP and Dr. Jenifer Vohs, Ph.D., HSPP 
Conducted individual Dialectical Behavior Therapy with adult and adolescent patients with 
Borderline Personality Disorder, comorbid Substance Abuse, and Disruptive Mood 
Dysregulation Disorder, co-led Dialectical Behavior Skills Group with adolescent girls 
presenting with Disruptive Mood Dysregulation Disorder and emerging features of Borderline 
 Personality Disorder, conducted cognitive/neuropsychological screening assessments, completed 
integrated assessment reports 
 
Indiana University – Bloomington           2014
  
Cognitive Behavioral Therapy Research and Training Clinic Coordinator  
Supervisors: Dr. Cara C. Lewis, Ph.D., HSPP and Dr. Brittany Brothers, Ph.D.  
     
Conducted brief intake assessments and suicide risk screenings, responsible for client case 
assignment, case management, and case file quality assurance 
 
Clinical Supervision and Mentoring Experience 
 
Indiana University – Bloomington            2015-2017 
Peer Supervisor, Cognitive Behavioral Therapy Research and Training Clinic 
Supervisor: Dr. Brittany Brothers, Ph.D. 
Supervised beginning Cognitive Behavioral Therapy clinicians, held ongoing supervision 
didactic meetings with Dr. Brittany Brothers, conducted review of therapy session 
videotapes, provided feedback to trainees regarding Cognitive Behavioral Therapy core 
competencies, rated supervision sessions for adherence and competence using the 
Supervision, Adherence, and Guidance Evaluation (SAGE) Rating Scale. 
 
Indiana University – Bloomington           2014-2016 
Peer Supervisor, Parent Child Clinic/Parent Behavior Training Clinic 
Supervisor: Dr. John Bates, Ph.D. 
Supervised beginning Parent Behavior Training clinicians, conducted live observation of 
clinical sessions, rated clinicians on Parent Behavior Training adherence and competence 
using standardized measures. 
 
Clinical Teaching Experience 
 
Centerstone – Nashville, Tennessee             July 2015 
Workshop Trainer, Consultant 
Topic: Measurement-Based Care 
Population: Adult Mental Health Clinicians 
Conducted workshop training and ongoing triweekly supervision and consultation in the 
application of Measurement Based Care 
 
Wolverine Human Services – Vassar, Michigan      March 2015 
Workshop Trainer  
Topic: Measurement-Based Care 
Population: Adolescent Residential Mental Health Clinicians 
 
Indiana University - Bloomington        March 2014 
Workshop Trainer  
Topic: Patient Health Questionnaire-9/Measurement-Based Care 
 Population: Research Assistants 
    
Research Mentoring Experience 
 
Indiana University – Bloomington          2016-2017 
Graduate Student Honor’s Thesis Mentor 
Honors Student: Hannah Kassab  
Project Title: The Differential Influence of Standardized versus Tailored Measurement-Based 
Care Training:  Outcome, Predictors, and Moderators 
 
Indiana University – Bloomington         2015-2016 
Graduate Student Honor’s Thesis Mentor 
Honors Student: Elena Navarro  
Project Title: Who is influential? A Social Network Analysis of Measurement-Based Care 
Implementation 
 
Indiana University – Bloomington         2014-2015 
Graduate Student Honor’s Thesis Mentor 
Honors Student: Meredith Boyd  
Project Title: Key Characteristics of Mental Health Trainers: The Creation of the Measure of 
Effective Attributes of Trainers 
       
General Teaching Experience 
 
Indiana University – Bloomington         2015 
Instructor of Record: PSY-P211 Research Methods in Psychology 
 
Indiana University – Bloomington         2012/2013 
Graduate Associate Instructor 
Courses: PSY-P319 The Psychology of Personality, PSY-P350 Human Factors and 
Ergonomics   
    
Leadership and Service 
 
Elected Clinical Science Student Representative       2016-2017 
Indiana University-Bloomington  
 
Editorial Responsibilities 
 
Ad Hoc Reviewer 
Journal of Consulting and Clinical Psychology 
Cognitive and Behavioral Practice 
 
Professional Memberships 
 
Society for Psychotherapy Research, Member     2010-Present 
 Association for Behavioral and Cognitive Therapies, Member  2012-Present 
     
Additional Trainings and Skills  
 
Technical/Statistical Skills 
Data Analysis in R, SPSS, MPlus 
Qualitative Data Analysis in NVivo, Atlas.ti 
 
Specialized Clinical Training – Treatment Modalities 
Cognitive Behavioral Therapy (CBT) 
Behavioral Activation (BA) 
Exposure Therapy (Specific Phobia, Panic Disorder) 
Parent Behavioral Training (Parent Management Training) 
Motivational Interviewing (MI) 
Dialectical Behavioral Therapy (Individual and Group DBT Skills) 
 
Specialized Clinical Training – Assessments 
American National Adult Reading Test (AMNART) 
Semantic Fluency – Animals 
Benson Complex Figure Copy 
Boston Naming Test (BNT) 
Brief Visuospatial Memory Test-Revised (BVMT-R) 
Controlled Oral Word Association (COWA) 
California Verbal Learning Test-Second Edition (CVLT-2) 
Frontal Assessment Battery (FAB) 
Finger Tapping Motor Testing 
Grip Strength Motor Testing 
Grooved Pegboard Motor Testing 
Indiana University Tokens Test (IU Tokens) 
Judgment of Line Orientation (JLO) 
Multilingual Naming Test (MINT) 
Mini Mental State Exam (MMSE) 
Montreal Cognitive Assessment (MoCA) 
Rey Auditory Verbal Learning Test (RAVLT) 
Rey Complex Figure Test 
 
Clinical Training Workshops 
Dialectical Behavior Therapy Training Workshop (2017-2018) 
Progressive Muscle Relaxation (2016) 
Cognitive Behavioral Therapy for Insomnia (2016) 
Cognitive Behavioral Therapy for Chronic Pain (2016) 
Dialectical Behavior Therapy (2015) 
Assertive Communication (2015) 
Acceptance and Commitment Therapy (2013) 
Motivational Interviewing (2013) 
Mindfulness-Based Cognitive Behavioral Therapy (2013) 
 Administration of the Structured Clinical Interview for the DSM-IV (SCID) (2010, 2014) 
Administration of the Hamilton Rating Scale for Depression (HRSD) (2010) 
Cognitive Behavioral Therapy workshop administered by Julie Jacobs, Ph.D. at the University of    
Pennsylvania (2010) 
Supportive-Expressive Dynamic Psychotherapy Workshop administered by Kathy Crits-
Christoph, Ph.D. at the University of Pennsylvania (2010) 
  
Other Professional Experience 
 
Cornell University Atkinson Center for a Sustainable Future          2006-2009 
Ithaca, NY  
Research Assistant and Intern 
 
Tri Tech Laboratories, Inc.,            2009  
Lynchburg, VA                    
Intern Chemist, Research and Development Laboratory 
   
Kolmar Laboratories, Inc.                         2005-2006  
Port Jervis, NY 
Junior Laboratory Technician, Research and Development Laboratory 
 
 
